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ABSTRACT
The central theme of this project was to develop a fraJnework for the MIT
Pharmaceutical Manufacturing JBenchmarking Study that would pr0J11ote organizational
learning through a process of "benchlnarking". This involved structuring relationships
with a number ofpharmaceutical conzpanies and developing qualitative and quantitative
peiformance measures to measure the peiformance afpharmaceutical manufacturing.
We argue that pharmaceutical manufacturing "viII play an increasingly strategic role
in the pharmaceutical industry of the future. Using manufacturing as a source of
cOlnpetitive advantage, however, ",'ill require fundanlental change within the
pharmcaceutical manufacturing organization. To be able to manage this change,
pharmaceutical companies ml-lstfocus on the defining their "current state" and their "desired
future state". Defining these states requires the use ofperformance measures that are
relevantfor the company. Pharmaceutical companies can use benchmarking as a means to
"learn" not only from other plan.ts but also from their own prior pClfornulnce.
In this thesis, we summarize important results obtained troln benchmarking 12
aifferent pharmaceutical plants over lnultiple .vears. The results provide valuable insights
into quality operations, inven,tory management, organizationalleaming and best-practice.
Thesis Supervisor: Professor Charles Cooney
Title: Professor of Chemical and Biochemical Engineering.
Thesis Reader: Professor Tom Allen
Title: Professor of Management
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Chapter 1
The Pharmaceutical Industry used to be highly successful
1.1 Profitability
Over the years, the global pharmaceutical business has been quite profitable.
Analyzing the pharmaceutical industry as recently as 1990 would have shown it to be more
profitable than any other industry in the U.S. As shown in Figure 1.1, net margins for
the top ten pharmaceutical companies were substantially higher than the S&P Industrials
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average of about 5%. They had been rising steadily. Figure 1.2 summarizes the return
5 10
on assets for the same group of global companies. Clearly, the industry was highly
profitable.
o
As a result of this profitability, pharmaceutical companies had rewarded
shareholders with returns on equity 50% higher that the median for Fortune 500 industrial
7
companies. The industry had benefited from healthy sales and earnings growth rates;
earnings growth had outpaced sales growth in almost every case.
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The basis for this profitability could be understood by analyzing the elements of the
1.2 Industry Structure
10o
pharmaceutical industry structure as shown in figure 1.3. This analysis can be broken
down into an analysis of the industry competitors, the entry barriers, the buyers, the
substitutes and the suppliers.
• Large fixed costs
The pharmaceutical industry is global with annual worldwide sales growing by
more than four fold from 1976 to 1990, when it reached $174 billion worldwide. As
shown in figure 1.4, the European market continued to be the largest regional market, and
the U.S. market was the largest single market for pharmaceuticals, accounting for 27% of
the world market in 1990. The Japanese market is the second largest with 18% of the world
market. Japanese pharmaceutical firms are generally small and tend to serve their domestic
needs, thus contributing to a pharmaceutical trade deficit in Japan of $1.9 billion in 1989.
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Entry Barriers
• Large economies of scale
• Proprietary product differences
• Large switching costs
• Access to distribution
• Proprietary R&D
• Proprietrary Learning curve
• Cost of FDA regulation
Suppliers
• Low threat of forward integration
• Less differentiation
• Low cost relative to total purchases
• Low impact of inputs on cost
or differentiation
• Large switching costs
Industry Competitors
• Large fixed costs
• Product differentiation
• Large switching costs
• Informational complexity
• Patent protection
• Exit barriers
• Value added
Buyers
• Low concentration of buyers
• Product differences
• Poor buyer information
• Low ability to backward integrate
• Few substitute products
• Few decision maker incentives
• Low priceltotal purchases
• Large buyer benefits
Substitutes
• Low buyer propensity to substitute
• Switching costs
• Poor relative price performance
• FDA regulation
• Proprietary technology
Figure 2.3: Elements of Pharmaceutical Industry Structure
In Europe, Germany was the largest market and was also a dominant exporter to other
European countries.
Fi ure 1.4: Worldwide Pharmaceutical Sales b
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investment in R&D. As shown in figure 1.5, compared with other major U.S. industries,
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the pharmaceutical industry devotes a higher percentage of its sales revenues to research
Fi ure 1.5: R&D Ex enditures as a ercent of sales
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and development.
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There are significant economies of scale and scope in pharmaceutical drug
development. While the cost of developing a new drug (average R&D cost per drug) was
as high as $80 million between 1970 and 1979, as shown in Figure 1.6, only 3 out of
every 10 drugs introduced between 1970 and 1979 subsequently recovered their R&D
costs.
Fi ure 1.6: Earnin s erformance of 100 Dru s vs. R&D Cost
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Hence, most companies had a few blockbuster drugs which paid off for all the
failed attempts. This is shown in figure 1.7 which shows that the top three drugs were a
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sizable fraction of each of the top ten companies total prescription sales in 1992.
• Product differentiation
The market for pharmaceuticals is highly differentiated by therapeutic category as
shown in Figure 1.8. As a result, the pharmaceutical industry is also highly fragmented.
The share of total sales held by the 20 largest firms accounts for 75% of industry sales; all
other firms account for 25% of the market. None of the major companies holds more than
a 7.5% share of the market.
Figure 1.8: Drug Sales
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The industry benefits from significant patent protection. This enables it to derive
value from its large fixed costs by excluding others from benefiting from the innovation for
a period of time (patents typically last 17 years).
• Entry Barriers
As shown in figure 1.3, there are significant entry barriers to getting into the
pharmaceutical industry. This has to do with the large fixed costs reflected in economies of
12
scale, the proprietary product differences, large switching costs due to the some degree of
brand loyalty among doctors and patients, the lack of access to distribution channels,
proprietary nature of R&D, proprietary learning curves and the huge cost of compliance
with FDA regulation.
• Buyers
The pharmaceutical industry has had a unique relationship with the buyer. There
has been very little buyer power due to the low concentration of buyers as each one often
makes decision individually. There is also significant product differences and extremely
poor buyer information. The buyer has no ability to backward integrate into pharmaceutical
manufacturing and has few substitute products. Interestingly, the actual decision maker
has traditionally been the doctor who have little or no incentive to be price sensitive. In
addition, pharmaceuticals are typically viewed as being a low price relative to the other
associated purchases of health care as shown in figure 1.9.
Fi ure 1.9: U.S. Healthcare Ex enditures as a Percent of GDP
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• Substitutes
Pharmaceuticals (brand name or generic or biotechnology based) tiave often been
quite cost-effective with few, if any.. effective substitutes for them. The lack of buyer
infonnation leads to large switching costs. Most substitute have typically had poor price
perfonnance relative to the pharmaceutical drugs. FDA regulation and the proprietary
nature of the technology also make it difficult for substitutes to take hold.
• Suppliers
The proprietary nature of the technology, associated with the asset specificity and
large fixed costs make the suppliers a low threat for forward integration. The suppliers are
typically less differentiated and hence have less bargaining power. The costs of material
supplies is typically low when compared to the total purchases of the pharmaceutical
industry and the inputs have a low impact on cost and differentiation. There are however,
large switching costs associated with suppliers to the pharmaceutical industry mainly due to
FDA regulation and compliance. This can sometimes determine the nature of relationships
with suppliers.
14
Chapter 2
The pharmaceutical industry in a state of transition
There has been a very significant change in the structure of the pharmaceutical
industry in recent years. Figure 2.1, shows the global pharmaceutical industry coming
Figure 2.1: Increasing pressure on the pharmaceutical industry
under increasing pressure. These include government pressure on prices and profitability,
increased bargaining power on the side of the buyer, increased threat of therapeutic and
generic substitution, stringent regulatory requirements, rapidly changing technology and
the threat of new entrants within the context of longer product development time scales,
more complex drugs and the increasing costs of research and regulatory compliance. In
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this squeeze, the industry needs to assess the efficacy and effectiveness of its research,
manufacturing and marketing operations. Given these competitive pressures it is becoming
increasingly apparent that pharmaceutical industry profits will almost certainly decline in the
next few years.
2.1 Increased competition between firms
Pharmaceutical R&D is increasingly risky and costly. As shown in figure 2.2, on
average, it costed $359 million in 1990 to bring a new drug through discovery, clinical
Fi ure 2.2: Cost of Develo in a New Dru
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testing, development and FDA approval to begin marketing. This cost had increased
sharply in recent years. Major contributions to the increased cost include the intricate
nature of modem research, failed products and regulatory hurdles. In addition, the focus
has shifter toward chronic and degenerative diseases; complicated and extensive clinical
testing is often necessary to prove efficacy of new medicines.
The nature of the pharmaceutical industry is changing. Presently, an important
dimension in the rivalry between pharmaceutical rums is the race to gain a foothold in the
generics market. The U.S. market is by far the most susceptible to generic substitution. It
is estimated that the U.S. market is about 25 percent generic, while Japan is close to 19
percent and most European markets are less than 10 percent generic-substituted. This is
having a profound effect on U.S. -ethical drugs companies who rely heavily on their
16
domestic market. The product life of most brand name pharmaceuticals has now effectively
been reduced significantly by the success of generics. The strengths of these companies
will erode if they are not hedged against the onslaught of generic substitutes. Hence
increasingly pharmaceutical companies are focusing on manufacturing and reducing
manufacturing costs.
The increased fixed cost of research and the higher risks together with the reduced
revenues are also leading to a rapid consolidation within the industry as pharmaceutical
companies enter into an increasing number of alliances and competitive agreements as
shown in figure 2.3.
Figure 2.3: Pharmaceutical companies have entered into an increasing number of
strate ic alliances and coo erative a reements
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2.2 Increased government pressure
The relentless rise in U.S. health care expenditures has resulted in health care costs
exceeding $800 billion per year (14% of the U.S. Gross National Product). As shown in
figure 2.4, health care expenditures have been doubling or tripling every decade. This has
resulted in government pressure on pharmaceutical prices and profitability.
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As national healthcare expenditures continue to rise, figure 2.5 shows that drugs as
a percentage of national health expenditures declined from 1965 to 1980, and have
Fi ure 2.4: National
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remained steady at a modest level since then. Outpatient drugs account for only five
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percent of each health care dollar. All drugs account for only about seven percent.
However, although pharmaceutical costs as a percentage of total health care expenditures
are small and decreasing, profitable drug companies are easier targets for cost reduction
than hospitals or physician services.
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2. 3 Increased buyer pressure
Historically, drug companies have profited from their unique relationship with their
customers. Insurance companies, not the user (patient) often pay for prescription drugs.
In addition, the prescriber (physician) had little incentive to choose a lower priced drug in
favor of a higher priced drug. However, this situation is changing. The buyers (insurance
companies and HMOs) have begun to join forces to increase their bargaining power and
hence force the pharmaceutical companies to lower their prices.
Figure 2.6 shows the effect of this change. As seen in the figure, the rate of
Fi ure 2.6: Dru Prices
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increase in pharmaceutical drugs prices has begun to fall under increased government and
buyer pressure.
2.4 Increased threat of substitution
The monopoly of the pharmaceutical company is usually protected in the form of a
patent. However, prescription drugs are increasingly coming under the threat of
therapeutic substitution (during the patent life) and generic substitution (immediately after
the patent has expired). Figure 2.7 shows the expected dramatic growth in generics in the
1990s. It was estimated that 200 drugs will come off patent by the year 2000.
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Figure 2.7: Growth of Generics
Similarly, biotechnology is beginning to playa large role in therapeutic substitution
as biotechnology products begin to become therapeutic alternatives for some conventional
phannaceutical drugs. At the end of 1991,21 biotechnology medicines had been approved
by the Food and Drug Administration. Meanwhile, as shown in figure 2.8, there are
mounting number of genetically engineered drugs and vaccines in clinical trials and at the
FDA for review.
2 . 5 Increased RegulatoI'Y Requirements
The Food and Drug Administration (FDA) continues to have stringent requirements
for safety and efficacy. The large number and increasing complexity of New Drug
20
Fi ure 2.8: Biotechnolo Medicines for Clinical Develo ment
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Applications (NDAs), in tum, have led to a backlog at the FDA. This adds to the time and
cost involved in drug development.
2.6 Rapidly changing technology and threat of new entrants
The level of sophistication and the volume of available data in fields relevant to
traditional pharmaceutical research like chemistry, physiology, and pharmacokinetics are
increasing rapidly. Biotechnology is a fast-growing and research-intensive technology that
poses a great threat to traditional pharmaceutical products. Figure 2.9 shows the percent of
total projects that are biotechnology related. With the advent of biotechnology, smaller
companies are now able to develop drugs that rival (or even surpass) those of the
established pharmaceutical companies. This has increased the threat of new entrants.
2.7 What is an appropriate response?
It is clear that the pharmaceutical industry is in a state of transition. What is not so
clear is how the brand name pharmaceutical, generic and biotechnology companies are
going to respond to this increasingly hostile environment. Typical responses over the last
2-3 years has been to decrease marketing and manufacturing costs, increase R&D
productivity and form alliances both vertically along the value chain and horizontally
between companies with complimentary products or competencies (Porter, 1985).
21
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Figure 2.9: U. S. Biotechnology R&D
This thesis will focus on understanding the role that manufacturing may be able to play to
help pharmaceutical companies compete in this more difficult environment.
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Chapter 3
Project Goals
3.1 Pharmaceutical Manufacturing Benchmarking Project:
The research described in this thesis is part of a larger study being conducted at
MIT under the auspices of the MIT Program on the pharmaceutical industry. The MIT
Program on the PhaITIlaceutical industry is a large interdisciplinary and on-going industry
study at MIT that attempts to understand the key detenninants of competitiveness within the
global pharmaceutical industry. Some of the projects that are currently underway within
the program are investigating issues of R&D productivity, project management, cost of
capital, manufacturing and drug pricing.
This project describes work that was done as part of the focus on pharmaceutical
manufacturing. The purpose of this project was to understand the role of manufacturing
in determining competitiveness within the phannaceutical industry and to become a catalyst
in improving the perfonnance of pharmaceutical manufacturing. An important prerequisite
to being able to do so is to develop a means to measure pharmaceutical manufacturing
petfonnance. "Benchmarking" was determined to be a useful tool to do so and led to the
initiation of the Pharmaceutical Manufacturing Benchmarking Project.
The phannaceutical manufacturing benchmarking project is a large on-going and
multi-year study that attempts to provide answers to the following questions:
• How important is manufacturing in the pharmaceutical industry?
• How can manufacturing perfonnance be measured?
• How well do pharmaceutical companies do at manufacturing?
23
• How do pharmaceutical companies compare with other industries?
• How do pharmaceutical plants compare when compared across
• different sectors of the industry
• different countries/geographical area
• different technologies
• How much better can pharmaceutical companies be at manufacturing?
• How much money can be gained from continuing improvement in operations?
• How good are the best pharmaceutical plants at Inanufacturing?
• What are the important leverage points to focus on to maximize improvement?
These questions provide the basis for formulating a mission. The mission of the
Pharmaceutical Manufacturing Benchmarking Project is to:
a. Elucidate the role of manufacturing in the pharmaceutical industry.
b. Develop a set of metrics that can be used to detennine petfonnance.
c. Develop a framework that allows companies to compare perfoffilance across
plants/processes.
d. Compare performance at the plant/process level.
e. Quantify the opportunity for improvement by establishing best practices.
f. Provide a means for companies to continuously improve their perfonnance.
3.2 Thesis Project Goals:
This thesis project combines work I have done over the years as part of my Ph.D.
research in the department of chemical engineering and the research I was involved in as the
project coordinator of the MIT Pharmaceutical Manufacturing Benchmarking Project.
My specific goals in this project were to:
24
• Characterize the current state of pharmaceutical industry.
• Elucidate the strategic role of manufacturing within the industry.
• Develop a approach to structuring relationships between MIT and pharmaceutical
companies involved in the benchmarking study.
• Test traditional functional metrics on companies.
• Develop a framework for benchmarking manufacturing petformance.
• Develop a set of petfonnance metries for measuring pharmaceutical plant/process
perfonnance
• Test framework and metrics on companies.
• Describe and compare perfonnance based on results obtained.
The central theme of this project were to structure an appropriate framework for the
MIT Pharmaceutical Manufacturing Benchmarking Study that would promote
organizational learning through the process of benchmarking pharmaceutical
manufacturing.
25
Chapter 4
Structuring organizational learning through "benchmarking"
4.1 "Benchmarking"
4.1.1 Definition
Over the years, there have been many definitions of benchmarking. The Figure 4.1
shown below summarizes a compilation of these definitions done by Michael Spendolini
(Spendolini, 1992). Any of the definitions from this palette is a reasonably good summary
of the idea of benchmarking.
the
-Systematic E3
-Structured
-Formal -Process for
-Analytical
-Organized
-Evaluating
-Understanding
-Assessing
-Measuring
-Comparing
-Continuous
A -Ongoing
-Long-term
-Business practices
-Products
-Services
-Work processes
-Operations
-Functions
-Recognized
-Acknowledged
-Identified
-Organizations
of -Companies
-Institutions
that are as
~rganizationalcomparison
for the -Organizational improvement
purpose oj -Meeting or surpassing industry best practice
-Developing product/process objectives
-Establishing priorities, targets, goals
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-Best-in-class
-Wodd class
-Representing best pracitices
Figure 4.1: Palette of definitions for "benchmarking"
It is important to understand that there are four key attributes to benchmarking. The
first is that it is never over. Benchmarking is an continuous and on-going process. The
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second is that it is a structured means to assess the business practices. The third is that it
usually implies a comparison for the purpose of improvement. And finally, benchmarking
often involves some notion of "best practice".
4.1.2 When, Why, Whom, \\il.at, Where and How?
Any benchmarking study involves choices to be made regarding the when, why,
whom, what, where and how of benchmarking (McNair et aI., 1992).
• When to benchmark?
Benchmarking can be perfonned at any time. However, it is most effective when
the company feels the need for it. This need can be quite specific and be triggered by some
crisis or initiative within the company. This need can also be quite general and have to do
with the company's desire to improve itself in a proactive manner.
• Why benchmark?
A company should benchmark because it walits to improve its perlormance. It is
important that benchmarking be viewed as a tool for improvement rather than a tool to
assign blame to certain people or certain parts of the organization.
• Whom to benchmark?
Benchmarking can be done at different levels. As shown in Table 4.1 a company
can practice internal, competitive, industry or "best-in-class" benchmarking. Each of these
has its own set of advantages or disadvantages.
• What to benchmark?
There is a need to determine whether the benchmarking with focus on specific
processes, activities, or functions. It is also important to decide on the depth of the
27
Type
Internal
Table 4.1. Types of benchmarkine
Description Advants2es
Anal)'sis of practices within various • Data are often easy to collect
division/plants in same organization • Data are easier to interpret
• Limited focus
• Internal bias
Competitive Looks outward to identify how other • Identifies strengths & weaknesses • Data collection difficulties
direct competitors are perforrrjog of competition • Ethical issues
• Helps to level the playing field • Antagonistic attitudes
• Information is very relevant
Industry Extends to all other companies
within the same industry.
• Relevant information
• AlIQWS for identification of trends
• Seldom leads to performance
leaps or breakthroughs
ttBest·In-d~" Look across multiple industries
in search of Itbest-practices"
independant of source.
• Supports quantum leaps in
performance.
• Stimulating results
• Time consuming
• Difficulty transferring practices
ioto ditferent eovironment.
analysis to be petformed. Bench~arkingcan focus on specific departments or functions
(vertical benchmarlrJng) or they can focus on a specific process or activity (horizontal
benchmarking).
• Where to get benchmarking information?
Benchmarking typically builds on existing sources of information. An initial focus
is to be able to use any published or already publicly available infonnation. This involved
accessing previous benchmarking studies, annual reports of cornpanies and use of public
data bases. Benchmarking also typically involves getting confidential information from
within the companies and requires their cooperation.
• How to benchmark?
There are many ways to do benchmarking& The process of benchmarking was
broken down into 3 stages: Measurement, Analysis and Change.
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Measurement: This first stage identifying the scope of the benchmarking study,
identifying appropriate drivers and performance drivers and identifying the
organizations to benchmark.
Analysis: Analysis involves actual interviewing, developing a questionnaire,
gathering information from companies, analyzing the data and reporting the results.
This is then followed by an analysis of the data that is obtained.
Change: Actually implementing change involves communicating results, establishing
goals and developing action plans and monitoring progress.
Clearly, this is an on-going process as change is followed by another round of
measurement, analysis and change and so on. Benchmarking is an on-going process.
4.1.3 Benefits of benchmarking
As described in Table 4.2, benchmarking provides a company with a number of
T bl 4 2 8 fit r b h k-a e . . ene ISO enc mar 102
Rigor • Making sure targets are set high enough.
Overcoming disbelief • Convincing ourselves that we can do better.
Accountability • An ongoing process for nleasuring perfonnance and ensuring improvement.
Culture change • An outward looking company rather than one that is internally focused.
important benefits. The primary benefits are the rigor that is associated with
benchmarking, a means to overcome disbelief about being able to do better, a means to
provide accountability and a culture change to an outward looking company_
Benchmarking provides a means to knowing thyself. Each company can use
benchmarking as a means to understanding its own strengths and weaknesses. A clear
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understanding of one~elfand an appropriate target desired state are the critical prerequisites
for organizational change.
4.2 Performance metrics
A primary step in benchmarking is to develop a set of perlormance metrics. The
goal was to choose metrics that appropriately captured both the current state and provided a
means to set a target or goal state. A critical requirement for success is that the firm needs
to know where it wants to go and have a means to measure its progress towards that goal.
Only with defined goals and metrics of performance can one propose a path towards
success and measure progress towards that goal. But what were these performance
metrics? Which ones are most relevant? There were no clear answers to these questions
either within phannaceutical organizations or within academia. Hence our first task was to
define what the desired characteristics of these new perfonnance measures would and then
identify the major classes of such performance measures.
4.2.1 Desired characteristics in performance Metrics
• Must be directly related to manufacturing strategy
An important attribute of a performance measure is that it must be related to the
operations or manufacturing strategy (Maskell, 1991). Performance measures must
provide a means to know well an organization is achieving the goals laid out in its strategy.
This is particularly important because people concentrate on whatever is measured. The
manufacturing strategy, in turn, must be congruent with the overall corporate or business
strategy.
There are six key elements around which a manufacturing strategy can be built.
They are quality, cost, delivery reliability, lead time, flexibility, and employee relationships
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(Maskell, 1991). The amount of emphasis on each of these areas defines the
manufacturing strategy.
• Are simple and easy to use
It is important a performance measure is simple and easy to use. Otherwise it will
simply not be used.
• Provide fast feedback to operators and managers
A performance metric must be a means to provide fast feedback to operators and
managers. The faster the feedback the stronger the impact on perfonnance.
• Intended to foster improvement rather than just monitor
A petfonnance metric must be used to foster improvement in a positive way rather
than be a means to rnonitor or control. Otherwise the metric will not serve its purpose in
the long run.
• Primarily non financial in nature
While financial measures are important to be able to measure performance on a
common basis of money, they do not provide an easy way for shop floor level focus on
operational improvements. Hence we argue, that most petformance metrics should be
non-financial in nature.
• Vary between locations
The relevance of a particular petformance measure varies between locations. A
petfonnance measure that is relevant in one plant may not be as relevant in another plant
• Change over time as needs change
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The relevance of a particular performance measure also varies over time. The
importance of a particular perfonnance mea'iure changes as needs change.
4.2.2 Major classes of performance measures:
Similar to manufacturing strategy~ there are six key components of manufacturing
perfonnance. They are quality, cost, delivery reliability, lead time, flexibility, and
employee relationships (Maskell, 1991).
4.2.2.1 Quality:
Table 4.3 depicts the important issues that related to quality that need to be
measured and relevant component of these issues. While measuring quality perfonnance
within a manufacturing organization it is important to understand the definition of quality,
the vendor quality performance, the production quality petformance, the accuracy of data,
the amount of preventative maintenance and the cost of quality (PMA Measuring Quality
Perfoffi1ance Committee, 94).
t ·rttt ·T bl 43 Ia e .. mportan Issues o consl er re a In2 o qua I:y me rlcs
ISSUES Important components to address
Definition of Quality • FOnD, fit, function, reliability, consistency
Vendor Quality Performance • Delivery perfonnance and quality perfonnance
• Number of vendors
• Concerned about value added vs. non-value added activities
• Inspection is non value added
• Vendor certification vendor's use of SPC
• Measurin2 incomin~ Quality
Production Quality • Need methods to measure variances SPC
• SPC and Continuous improvement
• Percentage of repeat sales
$ Works frrst time
• Time between service calls
Data Accuracy • Inventory Accuracy Simplified counting
• Bill of Materials and Routing Accuracy
• Forecast accuracy
Preventative Maintenance • Reactive vs. Proactive
Cost of Quality • External, internal, prevention and appraisal costs.
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4.2.2.2 Cost:
Table 4.4 depict'i the important issues to consider relating to cost metrics.
tttt t·e .. mpor an Issues o consl er re a InR o cos me fl
ISSUES Important components to address
Waste Rate • The seven wastes - wa~tc of overproduction.
waiting. transportation. processing. stocks.
motion~ Inakin~ dcfecti \'c product~
Inv~ntory turns • WI? turns
• Turns hy product turns hy plant
• Valuauon of cost of goods ~o!d
V81 ue-added analysis • Value added anaJysi~ is related to cycle time
• Direct Lalxlf Productivity
• Valuin~ production l:olnpletions
Cost Froductivity • Cost productivity ~r unit
• Cost of adding value per unit
• Cost/output ratio
Overhead efficiency • Output per unit of overhead
System Complexity • Transaction per lot
• Pa~es per jot
Tabl 4 4
Important ideas to consider while designing cost metrics are waste rates, inventory turns,
value-added analysis, cost productivity, overhead efficiency and system complexity.
4.2.203 Delivery reliability:
Table 4.5 depicts the important issues to consider relating to delivery reliability
Table 4 5 : Imj!ortant Issues to consider reaardina delivery reliability metrics
ISSUES Important components to address
Vendor delivery performance • Certific..'-ation
• Days late: on time vs. late vs early.
• Variance
• Unpack and put-away
Schedule Adherence • Is one aspect of quality in production process
• Quality implies reduction of variability in product & process
• Do operators establish schedules
• Product Completions schedule vs completed
• Cell completiions schedule vs. completed
• Past due products
Order & Schedule changes
Customer service level
• How often is the order or schedule chan~ed
• Delivery perfonnance and quality
• FG inventory levels?
• Service level
• Delivery reliability
• Receipt vs dispatch
• No. of past due orders
Lost sales • What is the lost sales due to poor delivery reliability?
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metrics. Important ideas to consider while designing delivery reliability metrics are
vendor delivery performance, schedule adherence, order & schedule changes, customer
service levels and lost sales.
4.2.2.4 Lead time:
Table 4.6 depicts the important issues to consider regarding lead time metries. It is
important to understand that many problems are caused or are related to long cycle times.
High cycle times lead to high work-in-process inventory and often require that plants make-
to-stock rather than make-to-order. This also make it very difficult to make changes during
the process and leads to added complexity in the system and is often associated with
uneven loading of work centers. Long lead times make a manufacturing plant inflexible to
change. Hence, it is useful for manufacturing plants to focus in shortening cycle times.
Reduced lot sizes and synchronized production planning and control lead to reductions in
lead times. As shown in Table 4.6, the important issues to address when designing lead
time related metrics are the means of measuring cycle time, the D:P ratio, the set-up times,
the material availability, the distance of material movement, the machine up time and the
customer service time. It is important to understand the
t ·T hi 46 Ia e . . mportant Issues to consl er reear In2 ea Ime me rlcs
ISSUES Important components to address
Measuring cycle time • Detailed recording of cycle times
• Analysis of en~ineerin~ routing
D:P ratio • Delivery time to production lead time ratio.
Set up times • Leads to shorter run, smaller lots sizes, less WIP
Material Availability • How often is oroduction held up for lack of material?
Distance of Material Movement • How far does material travel?
Machine up time • Machine utilization levels
Customer Service time • Easiest measure of overall efficiency of production process
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difference between the production lead time and the delivery lead time. Production lead
time is the critical path time for purchase and production of material to product. Delivery
lead time is the lead time offered to customers
4.2.2.5 Flexibility:
One of the important attributes of a successful manufacturing plant is flexibility.
There are different kinds of flexibility. Flexibility can be with respect to changes in
production mix, changes in production volumes or an ability to quickly introduce new
products. As shown in Table 4.7, the important issues to consider regarding flexibility
Table 4.7: Important issues to consider regarding nexibility metrics
Position of differentiation
ISSUE
CommoDalit
New Product Introductions
Number of different rocesses
Number of different
metrics are the number of parts or materials, the commonality among them, the number of
different processes involved, the position of differentiation, the number of new product
introductions, the degree of cross training and the amount of space capacity.
4.2.2.6 Employee relationships:
Another important aspects of designing performance measures is the ability to
measure employee relationships. While they are exceedingly important, they are often
difficult to measure. Here we are trying to measure the morale, teamwork and involvement
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of people, leadership in working environment issues and environment and safety. Some
typical measures attempt to capture quality circle involvement, number of suggestions per
employee, number of suggestions put into practice, amount of training/education time per
employee and the number of skills per person.
Of course, it is impOl1ant to note that different metrics are important to different
comp3.l1ies. This is often related to the difference in their strategies and their critical success
factors. Hence, it is more likely that there will be families of different metrics that
correspond to certain strategies. These families are likely to focus on the core operational
processes in the organization and are likely to cut across functional departments.
Benchmarking must begin at the highest organizational level in order to understand the
drivers for success, e.g. cost, quality, perfonnance, etc. for each company or situation.
For example when comparing multisource vs. brand name phannaceutical fiIms, they have
different critical success factors and different core competencies; thus, there are different
drivers to their peIfonnance.
4.3 Organizational learning through "benchmarking"
In our view benchmarking is simply a means for structuring organizational
learning. It is not a solution. Rather, it is a process. Benchmarking provides a framework
for organizationalleaming by leading the company to focus on measuring performance and
measuring it against prior petfonnance within the plant and outside the plant in a manner
that allows the organization to constantly ask itself if it can do better.
It is important to understand that benchmarking is not the same as surveying or
business intelligence. The aim of benchmarking is to locate organizations that do
something exceptionally well and then to develop a data-sharing relationship with them for
the purpose of mutual learning. Benchmarking tries to close the gap between one
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organization and the rest of the field. It assumes that having data on how the best
organizations perfonn will be useful in increasing the internal rate of improvement.
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Chapter 5
Structuring learning through "lead benchmarking partnerships"
5.1 "Benchmarking" as. a basis for organizational change:
Any sustainable organizational change must involve changing the way organizations
think:. But how can this change be catalyzed? What are the requirements for change?
Figure 5.1 below depicts the different steps involved in catalyzing change within
Figure 5.1: Deckard Change Map for Pharmaceutical Manufacturing
BECKARD CHANGE MAP
FOR PHARMACEUTICAL MANUFACTURING
Why Change?
Determining the need for change
Determining the degree of choice about whether to change
Managing
during the
transition state
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the phannaceutical manufacturing organization. As shown in the figure, the first step is to
detennine the need to change and the degree of choice about whether to change. The next
step is to define the present state and the future desired state. There needs to be a means to
measure both the mental models and the perfonnance of manufacturing presents and also be
able to characterize a desired future goal state. Once these states are defined, then the
present state needs to be assessed relative to the desired state and the means detennined to
move from the present state to the desired state (Bcckard et aI., 1987).
Doing this however, requires that there are means to capture the mindset of people
within pharmaceutical organizations and means to measure both present and desired
performance. That, in turn, requires understanding the critical components of
phannaceutical manllfacturing petformance. Setting desired petfoffilance goals requires
understanding the ideal state and characterizing the best achievable state. Benchmarking
provides a means to capture these states thereby providing a means for organization
learning and change.
5.2 Learning is an iterative and collaborative process
In our opinion, the first step towards promoting learning and organizational change
is to be open to change ourselves. Clearly, we do not have all the answers. Moreover,
these answers could not be determined in isolation. Rather than work in isolation within a
university setting our strategy was to work closely with different pharmaceutical
organizations. In our opinion, that was where most of the answers were.
While the goal of this study is to eventually involve most of the pharmaceutical
companies throughout the world OUf first step was to test our ideas and learn from a small
number of representative companies. At this stage our goal was to \vork with companies
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that we expected would provide us with a sample of the variability in performance and
organizational mindset that we might expect to see from the larger world sample. Hence,
we chose to work with companies representing the different major sectors of the
pharmaceutical industry. Our strategy was to be able to sample the brand name
pharmaceutical, generic/multi source and biotechnology segments of the pharmaceutical
industry. This is shown below in figure 5.2. Within each industry segment we chose to
work with two companies with representative manufacturing plants.
World Pharmaceutical
Industry
Figure 5.2: Structuring the learning through lead benchmarking partnerships
Need to define metrics and refine them. Need to understand current thinking within
the pharmaceutical industry. Need to develop relationships.
5.3 Benchmarking Approach
Figure 5.3 shows the benchmarking approach that we followed during our
interactions with the lead benchmarking companies. The rust steps that was followed in
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any benchmarking trip was to identify the critical success factors of the manufacturing
organization. The qualitative one-on-one interviews provides this insight. An immediate
next step was to define the business processes that needed to be benchmarked. Most
pharmaceutical manufacturing organizations have functional organizations for production,
materials management, quality assurance and quality control, technical services and human
resource management. Each of these functions involved a set of business processes that
could be benchmarked. The next step was to identify the appropriate performance
indicators.
These petformance indicators when standardized, then formed a basis to measure
performance, identify best practices and improvement opportunities. The most important
part of this benchmarking approach was to understand that it should be a continuous on-
going process of monitoring progress and then going through another iteration of
benchmarking.
Figure 5.3: Benchmarking Approach
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An important goal of the benchmarking study was to determine the appropriate core
processes to benchmark. Organizations vary significantly in their organizational structure,
the products they make, the technologies they employ, the sophistication of their
accounting systems and often the tenninology they use to describe the similar concepts.
Any benchmarking study must provide a means to control for such variability. Only then
can comparisons be made across different companies and plants.
The purpose of a lead benchmarking firm is to provides us with a means to test out
this benchmarking strategy on a smaller set of representative firms. It was important to
understand what role a university program like the MIT Program on the Pharmaceutical
Industry can play in measuring, designing and catalyzing change within the phannaceutical
manufacturing organization. The MIT project has been designed to be restricted to the
measurement and analysis mode rather than being involved in the detailed implementation
of the conclusions that come out of the study. However, it was important to understand
that would be a long-tenn on-going study and that results would continuously be made
available to the lead benchmarking partners on a regular basis.
5.3 MIT Benchmarking project: when, why, whom, what, where and how?
The next step was to decide on answers to the when, why, whom, what, where and
how questions of benchmarking phannaceutical manufacturing.
• When?
Most of the MIT benchmarking trips were \\'hen companies themselves believed
that there was a need to understand the role of manufacturing. Benchmarking is a time
consuming process. Hence, the first step in determining when a company got involved in
the project was when it was clear that there was top management commitment to the
project. It was also important to identify a primary client within the organization who
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would be available to playa coordination role between the company and MIT. The MIT
benchmarking team typically then made a whole day trip to the plant site.
• Why?
The focus of the study was to understand the strategic role of manufacturing and
promote organizational learning by benchmarking pharmaceutical manufacturing efficiency
and effectiveness.
• Whom?
OUf goal was to initially focus our efforts at benchmarking within the
phannaceutical industry. The study would then be expanded to other industries. Once we
determined the number of plants that we wanted to work with, the next step was to choose
among the large number of plants within each sector. Since we expected that this would
require continuous ongoing interaction an important criteria 'f, /as easy access to the plant
and its personnel. Hence only plants within the U.S. were chosen to be lead
benchmarking partners in this stage of the study~ The study will be extended to other
regions of the world in the near future.
• What?
Our initial goal was to confme our study to departmental Oi functional performance.
The next goal of the benchmarking process involved benchmarking the core manufacturing
sub processes and required a cross-functional focus on the value chain and an
understanding of the linking of activities across the organization to meet customer
expectations in the most efficient and effective manner possible.
• Where to get information?
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Once within the company, most of our benchmarking information was obtained
from a set of qualitative interviews, a quantitative questionnaire, informal discussions,
telephone conversations, a detailed plant and facilities tour and other infonnation provided
by the company. A confidentiality agreement was signed with all such companies.
• How?
The initial trip typically involved describing the goals and the scope of the project.
At this time the company's interest in becoming a lead benchmarking partner was
determined and discussed together with the costs and benefits of the relationship.
The presentation was typically followed up with a detailed plant tour where the
benchmarking team developed an understanding of the primary process flow within the
plant and got a subjective feel for the work environment. The plant tour was typically
followed up with detailed qualitative interviews with different functional heads within the
manufacturing organization. This process was usually one on one and was meant to
capture the mindset of the different individuals towards manufacturing perfonnance and its
role in the company. At this stage, a quantitative performance metrics questionnaire is
explained and left with the company to fill out. A period of three weeks was typically
allocated for companies to fill out this questionnaire and send it back to MIT. We
anticipated that the time commitment will initially involve on the order of ten person days
from the partner firm. This includes discussion time and interviews as well as time to
access information associated with batch records, human resources, financial, results and
manufacturing facilities.
Given the sensitive nature of this project, confidentiality was a critical issue. A
confidentiality agreement was always signed between the MIT project team and the lead
benchmarking partner to protect the firms property rights. In addition, when the data is
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used to provide feedback to the companies, they will be sufficiently normalized and
aggregated such that a set of results could not be associated with any particular finn. Each
fmn, however, would recognize their own results and would be able to compare with other
company's data. In addition, future publications of methodologies and results would be
independent of the individual frrm's identity.
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Chapter 6
Pharmaceutical Manufacturing: understanding its strategic role
6.1 Characterizing mental models
Any organizational change must involve changing the mind of the organization.
Hence any benchmarking project that aims at improving pharmaceutical manufacturing
must be able to capture the both the present mindsets and be able to characterize ideal or
desired mindsets. Hence, the qualitative one-on-one interviews. The goal during these
interviews is to able to capture the mental models of various individuals within the
manufacturing organization. These mental models were to be used to understand ttle
present state of thinking within the phannaceutical organization regarding manufacturing.
Our strategy during these interviews was to pursue a dialog mode of inquiry
(Schein, 1988). The interviews were designed to be very open ended and unstructured.
The purpose in doing so was to provide an environment to capture the structure of the
mental models of the individuals within the organization rather than to reinforce our own
mental model structures. OUf goal was to be open to conlpletel)' new thinking and
opinions.
It is important to understand that a benchmarking study that aims to measure
performance can be viewed as being quite threatening by individuals within the
organization and can lead to a defensive attitude. By keeping the interviews open-ended
and unstructured our goal was to ensure that we captured the actual thinking of the different
individuals rather than their interpretation of what they thought we wanted to hear.
46
6.2 Pharmaceutical Manufacturing: assessing the old perceptions
The pharnlaceutical industry traditionally has pointed to R&D (also marketing
sometimes) as being the primary driver of success. The strategy for success has been to
increase R&D expenditures and improve R&D productivity. Manufacturing, on the other
hand, was relegated to a significantly less important role.
First, the conventional view has been that the manufacturing cost was such a small
fraction of revenues that it was not important. Hence, it represented a low leverage point to
improve perfonnance of the phannaceutical organization. Second, it was not clear if it was
even possible to improve manufacturing peIformance even if a company wanted to. The
perception within the industry was that most manufacturing decisions were already locked
in by the regulatory requirements of agencies like the Food and Drug Administration
(FDA).
Hence, the approach to phannaceutical manufacturing to simply make sure it was
"out of the way" and off the critical path. "Just don't screw up" was the attitude towards
pharmaceutical manufacturing. Clearly, most organizations, had a "defensive strategy"
towards manufacturing. This organizational mindset towards manufacturing determined
the strategic choices that the organization made regarding manufacturing.
Table 6.1 shows the major types of manufacturing choices as defined by
Wheelright and Hayes (Wheelright et aI., 1985). Most phannaceutical companies followed
a conservative or defensive strategy when marking both hardware (i.e. structural) and
software (i.e. infrastructural) choices.
Qualitative interviews provided a basis for understand manufacturing choices made
by the phannaceutical organization. Pharmaceutical companies typically built a number of
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different facilities in different locations. These plants typically had significant excess
capacity. Given the conseIVative defensive strategy, new technology was typically viewed
with skepticism. Hence, most equipment and process technology was typically quite old
and manual. Batch processing was the typical mode of operation. Most pharmaceutical
manufacturitlg plants were also highly vertically integrated.
MAJOR TYPES OF MANUFACTURING CHOICES
STRUCTURAL • Capacity Amount
Timing
Type
• Facilities Size
Location
Specialization
• Equipment/process technology Scale
Flexibility
Interconnectedness
• Vertical Integration Direction
Extent
Balance
INFRASTRUCTURAL • Vendors Number
Structure
Relationship
• New Products Hands off
Start-up
Modification
• Human Resources Selection and training
Compensation
Security
• Quality Definition
Role
Responsibility
• Systems Organization
Schedules
Control
Table 6.1: Major types of structural and inrrastructural manufacturing choices
The infrastructuf?J choices made by the manufacturing function were similarly
defensive (also called conservative). The manufacturing organization reflected the mindset
of the rest of the organization. Manufacturing choices towards vendors, new products,
human resources, quality and systems were highly conservative. Vendors were typically
kept at anns length for fear of losing proprietary technology and trade secrets. Similarly,
the introduction of new products was limited and designed to be separated from the routine
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manufacturing. Human resources choices at the higher level were typically influenced
significantly by educational backgrounds. Turnover was low& The definition of quality
was in terms of conformance rather than performance. Quality was overwhelmingly
defined in tenns of conformance to FDA specifications. Process quality was defined as
doing the same thing we did before while product quality was defined as producing the
same product that was produced before (and approved by the FDA). The systems were
usually driven by the quality assurance function whose primary goal was to ensure that the
products that left the plant was in compliance with the regulatory requirements.
It seems that most pharmaceutical companies traditionally have had a defensive
strategy towards manufacturing. Manufacturing was either isolated from most corporate
strategy decisions or was often reactive to strategies developed for R&D and marketing.
6.2 Pharmaceutical Manufacturing: its new strategic role
It seems clear, that traditional pharmaceutical manufacturing has been viewed as
being reactive to decisions made in other parts of the pharmaceutical organization. Table
6.2 shows the stages in manufacturing strategic role as described by Wheelwright and
Hayes (Wheelwright et. ai, 1985). In this framework, traditionally pharmaceutical
manufacturing can be viewed as being mostly in Stage 1.
There seems to be significant potential for pharmaceutical manufacturing to move
up from Stage 1 to Stages 2, 3 or 4. However, the first step in doing so is to change the
established mental models towards pharmaceutical manufacturing.
A important step in doing so is to understand that manufacturing or operations
strategy can and should support the business or corporate strategy (Moody, 1990).
Competitiveness in the pharmaceutical industry, is based on maintenance of a product
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STAGES IN MANUFACTURING1S STRATEGIC ROLE
STAGE 1 Minimize manufacturing's
negative potential:
H internally neutral n
STAGE 2 Achieve parity with
competitors:
"externally neutral R
STAGE 3 Provide credible support to
the business strategy:
a internally supportive"
Outside experts are called in to make decisions
about strategic manufacturig issues.
Internal, detailed management control systems
are the primary means for monitoring
manufacturing performance.
Manufacturing is kept flexible and reactive
lIindustry practice" is followed.
The planning horizon for manufacturing investment
decisions is extended to incorporate a
single-business cycle.
Capital investment IS the primary means for catching
up with competition or achieving a competitive edge.
Manufacturing investments are screened for
consistency with the business strategy.
A manufacturing strategy is formulated and pursued.
Longer-term manufacturing developments and
trends are addressed systematically.
STAGE 4 Pursue a manufacturing-based Efforts are made to anticipate the potential of new
competitive advantage: manufacturing practices and technologies.
"externally supportive ll
Manufacturing is involved "Up front" in major marketing
and engineering decisions (and vice versa).
Long-range programs are pursued in order to acquire
capabilities in advance of needs.
Table 6.2: St~ges in Manufacturing's Strategic Rule
pipeline that will ensure future revenues to reward investors and continue to finance the
process of new drug discovery. The traditional industry has financed its own growth
through profits while the newer entrants, utilizing the discoveries of biotechnology, have
relied on public and private equity financing. Hence, any factor with impact on financing
research will directly impact the competitiveness of the firms in the industry.
Manufacturing has a key role in being able to do so (Plossl, 1991). As shown in figure
6.1, research can be financed either by increasing revenues or decreasing costs. Given the
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intense price pressure and consolidation of buyer power, increased revenues have become
an increasingly difficult source of addition capital for R&D. Hence, increasingly,
pharmaceutical companies are looking towards reducing their costs and increasing their
R&D productivity as a means to maintaining reasonable shareholder returns. Marketing
and manufacturing are two areas that are being targeted for cost reduction.
r
Figure 6.1: A strategic role of manufacturing
Revenues High Research
Productivi ty
t
Research &
Development
Shareholders
Tax~
Marketing &
Admin.
Cost of Goods
Future
Revenues
Incremental Ftmds from
Improved Manufacturing
Low Research
Productivity
It is in this light that manufacturing takes on an increasingly important strategic role
for the industry. With the cost of goods sold (COGS) on average at 20-25% of revenues
and R&D at 12-15%, a 15% reduction in manufacturing cost can provide a 25% increase in
R&D funding. This increased R&D funding, in tum, leads to a stream of future revenues.
Clearly, even with revenue constraints, there is an opportunity for firms to improve their
long tenn competitiveness through manufacturing excellence. This is true whether the
phannaceutical company has a high or a low research productivity.
However, manufacturing has a significantly larger role to play (Suzaki, 1987).
Manufacturing should be viewed a source of competitive advantage. Profit is revenues
minus costs. While improving manufacturing can reduce costs and thereby increase
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profits, manufacturing should be used to enhance pre :its by increasing revenues (Goldratt,
1992). Manufacturing should be a source of advantage in cost, quality and flexibility.
Both quality and flexibility serve to enhance profitability by increasing revenues. This
involving manufacturing up front in major R&D and marketing choices and vice versa.
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Chapter 7
Learning by benchmarking functional areas
within manufacturing
7.1 Benchmarking functional areas involved in manufacturing
One of our first steps was to benchmark the different functional areas involved in
manufacturing. Ivlost manufacturing organizations had different functional groups for
production, finance, human resources, quality assurance and materials management.
Hence we defined a set of metrics to measure the performance within each of these
functional areas. Benchmarking functional areas within the manufacturing organization was
a low cost-low benefit strategy and allowed us to work within the existing organizational
structure and accounting systems of the different companies while providing us with an
opportunity to gauge opportunities for improving manufacturing effectiveness and
efficiencies.
7..2 Functional benchmarking questionnaire
Table 7.1 depicts the metrics used to measure petformance within each functional
area. As can be seen this first generation questionnaire contained approximately 75
different. The detailed functional questionnaire is in Appendix A. These metrics were
tested in 10 different plant representing generating approximately 15 sets of data (some
plants were measured on a multi-year basis). Some of the results are described in section
6.4. Typically the questionnaire became the responsibility of one person within the fum
who distributed the questionnaire so that it could be filled out by the individual functional
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heads. In general, filling out this questionnaire took approximately 60 man hours of work
and was done over a period of 1 to 3 months after the initial presentation to the company.
BENCHMARKING METRICS FOR FUNCTIONAL AREAS
PRODUCTION METRICS HUMAN RESOURCE MANAGEMENT ~/IETRICS
Are prod'n operations on lIT Total # of plant prod'n employees
How many total products are produced Prod'n employees / Total # of employees
Number products use dedicated facilities ~1aintenance employees / Prod'n employees
How many products produced year-round Prod'n employee turnover
Total number of lots manufactured Lo~t workday cases per 100 employees
Lots mfr right 1Sf time / Total lots mfr Prod'n employee job absence rate
Avg cycle time for products (wks) Percent employees involved in work teams
Avg raw mat'l inventory (wks) Avg weekly O.t. hrs for prod'n employees
Avg time req'd for line turnover (hrs) Avg brs of training / Total work hours
Avg number of Inter-plant transfers
Discard rate for fermentatIon operations QUALITY ASSURANCE/OPERATIONS METRICS
Number new products introduced into mfg Total complaints / Millions of units
Avg age of equipment used in mfg (yrs) Vendor lots aprv'd / Total lots rec'd
Average capacity utilization of facility Avg QC release time for raw mat'ls (hrs)
Average capacity utilization of manpower Avg <JC release tIme for F.G.'s (hrs)
Degree of automation (I-low, 5-high) Avg length of QC hold on F.G.'s (days)
New product ramp-up time (wks) Avg actual raw mat'l test time (hrs)
Total number lots mfr for top 5 products Avg actual finished good test time (hrs)
Number of years top 5 product5 produced
MATERIALS MANAGEMENT/HANDLING METRICS
Number dates missed / Total deliveries
Finished goods stock / Total Inventory
Work-in-process / Total inventory
Percent on-time del'vry from suppliers
FINANCIAL METRICS Total number suppliers for top 5 mat'ls
Prod'n O-H cost / Total cost of F.G.'s
Maintenance exp's / Total cost of F.G.'s OTHER MISCELLANEOUS METRICS
Sales / Number of prod'n employees (mil) Number suggestions by prod'n employees
Total value avg raw mat'l Inv held (mil) Number suggestions by maint employees
Total value of avg work-in-process (mil) Total number of ideas implemented
Total value of avg F.G.'s inv held (mIl) Actual sales / Aggregate forecast req't
Typical inventory holding cost Personnel dedicated to process improve't
Total cost F.G.'s / Total cost of G.B. SignIficant process-plant modifications
Plant value constructIon-purchase (mIl) Trigger for process-plant modifIcations
Year plant operational or purchased External (eg. FDA, EPA, Customer)
Discount rate used on plant value Internal (eg. Ideas, cant improvement, QC)
Table 7.1 Benchmarking metrics used for different functional areas
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7.3 Functional Benchmarking Results:
7.3.1 Human Resource Management
Table 7.2 shows 13 column of data involving 9 different plants. PI to P4 represent
active ingredient manufacturing plants. GO, G 1 and G2 represent bulk formulation and
packaging plants. Bland B2 represent biotechnology plants. When measured by the
number of plant production employees the biotechnology plants studied were significantly
smaller. There is a significant variability in the ratio of production employees to total
employees and the ratio of maintenance employees to production employees. There is
significant variability in the production employee turnove:. Both the ratio of maintenance
to production employees and the production employee turnover are abnormally high in the
case of the two biotechnology plants included in the table. The reasons for these high
numbers are not clear but it is noteworthy that both the plants have a very small number of
production employees. Hence the ratios could be skewed.
Table 7.2: Human Resource Management data
Measure PI P2 P3 P4 GO GI-90 GI-91 GI-92 G2-90 G2-91 G2-92 8193 B293
Total # of plant prod'n employees -- -- -- -- -- 229 233 230 324 318 316 3.5 7
prod'n employees / Total employees 420/0 500/0 730/0 79% 610/0 590/0 57% 55% 820/0 800/0 80% -
Maintenance/ Prod'n employees -- -- -- -- -- 120/0 120/0 12% 50/0 50/0 60/0 29% 14%
Prod'n employee turnover 1% 10/0 2% 3% 10/0 30/0 3% 40/0 5% 20/0 4% 290/0 430/0
Lost workday cases/1 00 employees 0.0 4.4 3.1 0.0 3.8 1.2 1.2 1.1 1.9 1.8 2.0 - -
Prod'o employee job absence rate 3% 4% 4% 3% 6% 4.0% 3.20/0 3.7% 20/0 20/0 20/0 - -
% employees involved in work teams 00/0 00/0 00/0 00/0 0% 48.0% 49.00/0 55.00/0 1000/0 100% 100% 100% 100%
Weekly 0.1. hrs for prod'n employees 10.2 4.0 14.0 4.0 4.3 3.0 3.7 2.1 2 2 2.1 4 1
Avg hrs of traini ng / Total work hrs -- -- -- -- -- - 5% 6% 10/0 10/0 1% 50/0 30/0
'" suggestions by prod'n employees Nffr 30 430 177 3 34 104 18 40 54 37 - -
#I suggestions by maint employees -- -- -- -- -- 21 68 12 3 1 5 - -
Total number of ideas implemented Nffr 12 301 67 0 12 33 11 43 39 37 - -
The number of lost workday case per 100 employees varies between 0 and 6%.
Production employee absentee rate varies between 2 to 4%. Similarly, worker morale and
involvement is captured by a number of metrics. The % of employees in work teams varies
wildly. Due to the highly subjective nature of defining involvement in work teams we
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suspect that it is more likely that the numbers in the table do not capture what was desired.
Worker weekly overtime range from 1% to 10.2%. 1-5% of the total work hours are
spent on training.
There is significant variability among the number of suggestions made by
production and maintenance employees among the different plants. The biotechnology
plants Bland B2 do not have formal suggestion mechanisms. Plant G2 takes an active
roles in the suggestion process and implements a large fraction of the ideas that are
suggested by employees.
7.3.2 Financial
Table 7.3 shows 11 columns of financial data obtained from 7 different plants.
Plants PI to P5 depict active ingredient plants while plots 00,01 and 02 depict bulk
formulation and packaging plants. As can been seen plot 02 has the higher production
overhead costs as a fraction of its finished goods costs. Plant G 1, on the other hand, has
the highest sales per employee.
Table 7.3: Financial data
Measure PI P2 P3 P4 PS Gl-90 Gl-91 Gl-92 G2-90 GZ-91 G2-92
Prod'n Q-H cost I Total cost ofF.G.'s 290/0 18% 34% 34% 13% 190/0 23% 30% 460/0 51% 52%
Maintenance exp's I Total cost of F.G.'s 4% 4% 8% 4% 5% - 1% 42% 4.10% 3.90% 3.600/0
Sales I Number of prod'n employees (mil $) -- 0.7 0.6 0.2 -- 3.8 3.8 4.2 0.4 0.5 0.6
rro13l value avg raw matl iov held (mil S) 11.6 3.4 17.0 4.1 5.0 8.2 8.8 13.1 9.1 9.8 14.6
!fotal Value of avg work-in-process (mil $) 28.6 30.1 43.3 16.2 3.8 7.7 8.5 9.4 1.2 1.3 1.8
Total value of avg F.G.'s inv held (mil $) 14.9 19.6 17.0 7.8 16.3 0.1 22.8 30.0 11.9 20.3 25.8
Typical inventory holding cost (%) 130/0 13% 130/0 130/0 90/0 9% 90/0 9% 8.50% 6.30% 3.60%
The active ingredient manufacturing plants PI to P4 have a significantly larger
amount of money tied up in inventory. Most of this difference in inventory is in the value
of the work-in-progress. Raw material, work-in-process and finished goods inventory all
all going up for plants Gland G2. Similarly the overhead costs are going up for both
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plants Gland 02. The inventory holding cost depicts the company's perception of how
much it cost the company to hold inventory.
7.3.3 Production
Table 7.4 depicts 16 columns of data describing productioIl data obtained from 10
different plants. PI to P4 depict active ingredient manufacturing plants, GO, G I and 02
depict bulk formulation and packaging plants and Bl, B2 and B3 depict biotechnology
plants.
It is clear from all the different plants visited that the plant personnel did not
perceive themselves as pursuing ajust-in-time manufacturing philosophy.
The data indicate generic bulk fonnulation and packaging plants deal with a larger
number of products compared to the biotechnology and active ingredient plants (not
shown). Also most bulk formulation and packaging plants do not have dedicated facilities
as a result. That is they use the same facility to make different products. In fact while
biotechnology plants make the same products year round, the bulk fannulation plants do
not make any of their many products year round. The bulk formulation plants make a
significantly larger number of lots per year. There is significant variability in the number of
lots that are manufactured right the first time.
The cycle time for products show significant variability. It is interesting to note that
there are no clear difference in cycle times between active ingredient manufacture, bulk
formulation and biotechnology plants. The raw material levels in terms of the number of
weeks that they would take to be consumed (this number is useful because it scales the
actual raw material level by the rate at which it is consumed) shows it to vary between 3
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weeks to 17 weeks. There seems to be some correlation between the lots manufactured
right the frrst time and the amount of raw material inventory.
There seems to be a clear difference in the time that it takes for line turnover. Bulk
formulation plants have a quicker turnover time of between 4 to 80 weeks. Active
ingredients plants, on the other hand have a significantly larger turnover time.
Biotechnology plants on the other hand are often dedicated and hence for some there is no
line turnover at all. Unlike bulk fonnulation plants, both active ingredient plants and
biotechnology plants petform a larger nunlber of inter-plant transfers. The reasons for this
are unclear but bring issues regarding interplant transfers. Only plants PI and P2 and the
biotechnology plants involves bioprocesses/fennentations. The discard rates indicate
variability in their performance. The larger discard rate of plant B3 is due to the use of
animal cell culture.
Probably because of the need to do multiple setups and change between products
the multi-product bulk formulation plants have lower capacity utilization levels when
compared to brand name active ingredient manufacturing plants and the biotechnology
plants. The biotechnology plant with their dedicated facilities had higher utilization levels.
However, they seems to be less automated. This may be to the inherently larger variability
in these bioprocesses which makes them difficult to automate. Bulk formulation plants
manufactured significantly more lots than the biotechnology plants.
7.3.4 Quality Assurance/Operations
Table 7.5 shows 11 columns of quality assurance/operations data from 7 different
plants. PI to P4 are brand name active ingredient manufacturing plants while 00,01 and
02 are bulk formulation and packaging plants. The number of complaints per million units
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Table 7.4: Production data
Measure PI P2 P3 P4 GO Gl..90 Gl..91 Gl-92 G2-90 G2-91 G2-92 BI93 8293 B391 8m 8393
J\re prod'n operations on lIT? No No No No No No No No No No No No No No No No
1# of products -- -- -- -- -- 48 46 44 222 226 221 2 4 3 4 2
Products with dedicated facilities -- -- -- -- -- 0 0 0 1 1 1 1 4 2 2 2
Wproducts produced year-round -- -- -- -- -- 0 0 0 - - 2 4 2 2 2
rrotal # of lots manufactured -- -- -- -- -- 1300 1329 1441 1440 1479 1411 44 134 20 34 25
lLots mfr right 1sr time I Total lots 760/0 750/0 810/0 280/0 80% 980/0 750/0 980/0 52% 490/0 430/0 68.200/0 99.30/0 450/0 500/0 760/0
(:ycle LJme for protlucts (wks) 19.8 9.3 21.0 29.0 15.8 17.0 16.3 16.3 23.0 23.0 23.0 34.0 12.0 22.0 22.0 26.0
vg raw mat1 inventory (wks) 10.0 4.0 8.0 16.0 3.0 6.0 5.0 5.0 7.0 7.0 9.0 3.0 3.0 17.0 17.0 17.0
Time for line turnover (hrs) 292 184 234 236 80 15 15 15 4 4 4 - 4 N/AP N/Ap N/Ap
# of inter-plant transfers 2 3 3 2 0 0 0 0 0 0 0 2 4 3 3 3
Discard rate for fermentations 5% 20/0 N/Ap N/Ap N/Ap N/Ap N/Ap N/Ap N/Ap N/Ap N/Ap 0 0 200/0 100/0 10%
# new products introduced -- -- -- -- -- 2 0 0 0 0 0 0 0 0 1 0
!Age of equipment used (yrs) 9 8 9 7 7 7 7 8 6 7 8 4 6 5 6 7
Capacity utilization of facility 700/0 85% 8~% 89% 65% 70% 75% 80% 50% 62% 740/0 100% 90% 85% 950/0 90%
Capacity utilization of manpower -- -- -- -- -- 870/0 920/0 97% 10% 60% 60% 950/0 95% 1000/0 1000/0 1000/0
Degree of automation (1-5) 3 4 4 4 4 3 4 4 4 4 4 2 2 2 2 3
New product ramp-up time (wks) -- -- -- -- -- 8 - - - - - 10 N/.Ap N/Ap
rrotal # lots mfr - top 5 products -- -- -- -- -- 908 950 1030 40 55 54 250 325 20 34 25
1# of yrs top 5 products produced -- -- -- -- -- 13 14 15 10 10 10 6 3 2 3 4
vary considerably. GO is clearly the best plant along this dimension while plant G2 not
only has the highest number of complaints but is actually getting worse over the 3 years
sampled.
Table 7.5: Quality Assurance/Operations data
Measure PI P2 P3 P4 GO GI-90 GI-91 GI-92 G2-90 G2-91 G2-92
Avg actual raw matl test time (hrs) 6 8 8 6 5 8 7.0 6.4 20 20 20
Avg QC release time for raw malls (hrs) 350 72 336 168 108 520 477.0 434.0 672 672 672
Vendor lots aprvtd I Total lots rectd 960/0 98% 950/0 98% 970/0 N/Av 99.90/0 99.6% 92.30% 97.500/0 90%
~vg actual finished good test time (hrs) 10 14 15 8 12 13 11.4 10.4 - - 4
~vg QC release time for F.Go's (hrs) 410 480 504 120 355 190 170.0 156.0 120 120 120
~vg length of QC hold on F.G.'s (days) 90 20 21 24 5 18 18.0 15.0 - 6
Irotal complaints / Millions of units 52 24 28 15 5 22 22 14 56.7 79.5 89.7
A large fraction of the vendors lots that are received, are approved. Plant G 1 has
the best record while once again plant G2 has the worse record. Plant 02 also has the
longest release time for its raw materials. Another particularly perturbing observation about
02 is that all its numbers are either constant or are becoming worse. This is in contrast
with plant G1 which seems to be improving along most of the dimensions.
There is considerable difference in the time required to actually test raw materials or
finished goods and the time for raw materials or finished goods release.
7.3.5 Materials Management
Table 7.6 depicts 11 columns of data obtained from 7 different pharmaceutical
plants in the U.S. PI to P4 describe brand name active ingredient manufacturing plants
while GO, Gland G2 represent bulk formulation and packaging plants over multiple years.
The table shows that six metrics uses to capture the performance of the materials
management function.
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The percentage on-time delivery from suppliers are higher for the active ingredient
manufacturing companies PI to P4 when compared to the bulk formulation and packaging
plants of GO, Gland 02. This is possibly because most chemical manufacturing plants
have fewer suppliers and have better relationships with them. Plant 02 has significantly
lower on-delivery performance from its suppliers. However its performance has
improvement over the three years sampled while the perfoffilance of plant G 1 has
deteriorated.
Table 7.6: Materials Management data
Measure PI P2 P3 P4 GO Gl-90 Gl-91 GI-92 G2-90 G2-91 G2-92
Percent on-time del'vry from suppliers 950/0 980/0 96% 97% 910/0 93% 920/0 90% 83.70% 86.70% 92.40%
Total number suppliers for top 5 mat1s -- -- -- -- -- 3.00 3 3 6 6 6
Raw materialffotallDventory 210/0 6% 22% 14% 200/0 28% 260/0 25% 48% 600/0 68%
Work-in-process / Total inventory 52% 570/0 56% 58% 15% 210/0 200/0 18% 7.60% 2.70% 2.20%
Finished goods stock / Total Inventory 270/0 370/0 22% 28% 650/0 510/0 540/0 57% 440/0 37% 30%
Number dates missed / Total deliveries 170/0 3% 3% 2% 7% 2% 2% 20/0 16% 13.20% 7.60%
Actual sales / Aggregate forecast req't 920/0 101% 91% 990/0 1090/0 - ~ - 91.80% 103% 96%
This lower on-delivery for bulk formulation plants correlates with them having to
keep a larger fraction of their inventory as raw material inventory. However, bulk
fonnulation plants also maintain higher fractions of inventory as finished goods inventory
when compared to a active ingredient manufacturing plants. The number of due dates
missed/total deliveries metric indicates that this varies between 2% to 17%. These higher
fractions of inventory finished goods inventory, however, do result in higher customer
service levels in the case of G1 but do not in the case of 02. Another clear characteristic is
that active ingredient manufacturing plants have a significantly higher fraction of their
inventory as work-in-process inventory. This could have many reasons including a larger
number of processing steps, inherent complexity, larger batch sizes, larger cycle times or
just poor inventory management. The actual sales/aggregate sales metric indicates that
sales vary between 91 % and 109% of the forecast.
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7.4 Limitations of the functional approach to benchmarking
Clearly, this functional approach to benchmarking provided us with some valuable
insights into pharmaceutical manufacturing. Some clear trends were highlighted and some
important questions raised. However, using the different functional groups within
pharmaceutical manufacturing as a basis for benchmarking is a low cost low benefit
strategy. It is low cost because it works within the existing functional organization
structure of the organization and looks at perfonnance measures based on who performs a
particular task. For example, the vendor lots approved is a quality assurance metric simply
because QA actually approves or reject a lot. This information is easy to get because it is
requested from the function that actually does the testing. However, this is of low benefit
because it continues to drive the organization to think vertically in teffils of its own
functions. What we want the performance measures to do is to lead people to think
horizontally in tetmS of the different functions together trying to satisfy a customer. It is
more important to think in terms of what the customer wants and how value is created
along the way than simply each function by itself. Hence, the petformance measures and
the benchmarking should focus on the activities that a manufacturing organization has to
perlonn rather than who petforms it.
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Chapter 8
Learning by benchmarking core processes within manufacturing
8.1 A generic process flow diagram for pharmaceutical manufacturing
Pharmaceutical manufacturing involves many different methods to make different
kinds of products. There are a wide range of technologies involved. Each manufacturing
process can be very different and can have different starting and ending points. In
addition, there is significant variability in the number of steps involved in manufacturing a
pharmaceutical. In addition, many of these steps could be perlonned in different facilities
within the same location, completely different locations within the same company or in
completely different companies. This makes it difficult to be able to compare manufacturing
processes.
Hence, one of our early goals was to formulate a generic but simplified process
flow diagram for pharmaceutical manufacturing. The goal in doing so was to ensure that
the process flow diagram was at a generic or high enough level that would allow each plant
to identify with it, while low enough or specific enough such that we would be able to see
variability in manufacturing effectiveness and efficiency across these same plants. Given,
this generic process flow diagram we could further customize it for each different plant if
required. This idea of a generic flow diagram was important because it allowed us to
visualize the flow of materials through a manufacturing plant using a common set of
building blocks. This was important because it allowed us to discuss industry structure,
relationships with suppliers and customers and different dimension of inventory
management and quality operations. In addition, the process flow diagram provided us
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with a systematic starting point to formulate appropriate performance metrics to measure
manufacturing efficiency and effectiveness.
Figure 8.1 shows the silnplified generic process tlow diagram for pharmaceutical
manufacturing. As can be seen, this process flow diagram consists of three kinds of
primary building blocks: material processing or production, inventory and quality control.
Each of the them is represented graphically as a different geometric shape.
The shaded rectangles depict manufacturing or production or actual material
processing steps. Each shaded rectangle is actually an aggregated description of a number
of more detailed steps (on the order to one to thirty different material processing steps).
These are the steps that involves actually changing the physical or chemical state of the
material or its surroundicgs. Typical material processing steps include fermentation,
centrifugation, mixing, cell disruption, filtration, formulation, tableting, filling and
packaging.
The circles depict quality control steps. They are usually designed to ensure the
quality of the product produced at the preceding step. There is a strong regulatory
component to this operations and quality control is typically coordinated with the function
of quality assurance. Once again, it is important to understand that this is a simplification.
There are typically a number of QC steps after (and sometinle before and during) many of
the individual material processing steps. The distinction between a QC step and a material
processing step in that the QC step does not change the nature of the material. It is usually
designed to test certain properties of the material at different points along the process flow
diagram.
64
t
t
t
,..-a ..
~
-= ..
~
-=
~
I
e
I
e
I
I
e
I
~
~
~
:=
:=
:=
~
I
..c
I
..c
I
I
..c
I
·C
:s
:s
= ....
.....
a-
I
fIj
I
fIj
I
I
fIj
I
=
Q
...
Q
-
Q
CJ
~
L
...J
...J
L
...J
===e-;
c
.~-
z
= ~
...
CJ
~
=
~
e
~
a-=
~
U
..c
:;
~a-
c
;:J
.s
<
z
e
~
~
Q
=a-
~
~
~
=
z
=a
0
~
~
~
~
e
~
C(I.)
00.
e
(I.)
~
00.
Z
CJ
~
...
e
u
r-1
~
>
CJ
0
...~
·C
~
U
~=
~
<
~~"0~C....- ~e....rIJ~aC~a-= ~r;
The triangles depict inventory. This is typically a non-value added step and usually
involves material that is waiting to be processed, analyzed by QC or shipped. Once again,
the process flow diagram simplifies the concept of inventory by showing it in an
aggregated manner. Inventory is built up before and after each individual processing and
QC step. Inventory levels are important to understand because they are often symptoms
that can help characterize manufacturing effectiveness and efficiency.
The arrows within the diagram that go from left to right indicate a flow of material
along the process flow diagram from raw material to final product In addition, there are a
few dotted arrows indicating waste and rejects by QC and possible reprocessing. There
dotted arrows are meant to indicate waste, rework or reprocessing. These are important
measures in detennining quality petformance.
Another importani feature of the process flow diagram is that it breaks up the
manufacturing process into three main types of manufacturing: active ingredient
manufacturing, product formulation and packaging. While the distinction is not always
clear, active ingredient production, fOImulation and packaging are usually very different
kinds of processes. Active ingredient manufacturing usually involves modifications in the
chemical nature of the materiaL Most processing steps involve principles of chemistry or
biology. Active ingredient manufacturing is usually a series of a large number of steps. It
is usually more proprietary in nature. Typical steps include fennentation, centrifugation,
filtration, and extraction. Bulk formulation, on the other hand, typically involves changing
the physical nature of the product. Fewer steps are involved. Most processing steps
involve principles of physics. Examples of fOffilulation steps include mixing, tableting and
polishing. Packaging using involves changes to the products surroundings rather than the
product itself.
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In each of the three stages there is a need to bring in raw materials from the
previous stage. This involves doing Q<: analysis and is often associated with inventory.
For active ingredient manufacture the raw materials are typically from chemical
manufactures. The materials coming in the bulk formulation stage could be either from the
same plant, a different plant within the same company or from a totally different company.
This is also the case for package although, formulation and packaging are typically in the
same facility. Each of these stages can used either directly sell that stage's product or to
provide material inputs into the next stage.
8.2 Determining the appropriate levels of benchmarking
As described in the previous chapter, the benchmarking of the different functional
areas involved in manufacturing was a quick low cost- low benefit means to quickly gauge
the opportunity that may exist for improving phannaceutical manufacturing. This fIrst pass
approach offered us some insights into the supplier relationships, inventory levels and the
cycle times for quality assurance. Clearly, there is an opportunity for improvement.
However, this opportunity \vas still defined very vaguely and did not provide a means for a
company to take action or for us to detennine the underlying causes of the inefficiencies.
At this aggregate level it was also very difficult to compare across companies.
One of the first decisions to make at this stages, was to determine the appropriate
level to do the next phase of benchmarking. As shown in figure 8.2 below, benchmarking
could be done at a number of different levels. At the level of the pharmaceutical
organization benchmarking if often done in terms of metrics like the return on investment
(RGI). While this might be a useful metric, it is too aggregate and does not help a
manufacturing plant target its improvements. Similarly, at the level of the manufacturing
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organization, the benchmarks of the functional areas are still too aggregate to help target
improvement.
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Figure 8.2: Determining the appropriate level of analysis for benchmarking
We believe it is necessary to go down to the level of the five core manufacturing
sub-processes. It is important for benchmarks to at least be at this level of disaggregation
because not all companies or plants perform all the five sub processes. Hence they would
be difficult to compare at the overall plant level. Rather, comparison should be made at the
sub process level or below. As shown in the figure above, most of the sub processes
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consist of a number of process steps that typically include production, inventory and
quality control. We believe that the process flow diagram should be the basic vocabulary
for benchmarking and benchmarks need to be determined around this generalized process
flow diagram.
There are, however, different levels of detail at which the process flow diagram can
be written. Processes when described completely typically involve upto a few hundred to a
few thousand steps. For this study, we determined that the level of detail for the process
flow diagram benchmarking was to be determined by a cost-benefit tradeoff. Figure 8.3
depicts our Perceived cost benefit tradeoffs.
t
BENEFIT
Individual activities
Iprocess steps
Core activities within
manUfacturing subprocesses
Manufacturing
subprocess level
/ Manufacturing process Level
Organization Level
COST
Figure 8.3: Perceived cost benefit tradeoff for different levels of analysis.
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Our perception, as can be seen from this figure was that benchmarking at the core
sub-process level at the level of 2-4 aggregated steps per sub process would give us the
best cost-benefit tradeoff. Within each manufacturing sub process, our goal was to lump
the processing, QC and inventory steps. By analyzing these three aggregate steps for each
sub process for any manufacturing plant we believe we can both be generic enough to be
able to compare across plants while being specific enough to be able to capture variability
across plants and companies. Hence, our strategy was to go down one level, once again
determine the opportunities for improvement that are highlighted at this level and then
detetmine if another level of detail might be required. Benchmarking is a continuous
process and once again, we decided to follow a "learning by doing" strategy.
8.3 Systems Thinking: inputs, outputs and a context
Each of the sub process could not be analyzed functionally. Our belief was that the
functional approach hid many of the underlying issues. The functional approach led us to
perfonn benchmarking based on the functional silos within the organizational chart. While
this was easy to do because most people and infonnation were organized in this manner, it
was not as useful. This was because it did not address the underlying activities that the
organization performed. Rather, the process flow diagram seems to be the more
appropriate framework to use for benchmarking manufacturing; it follows the addition of
value to the product as it moves from raw material to final product. However, this activity
or process flow based approach would only be useful if there was a consistent and
systematic means of assessing petformance along the process flow ..
That led us towards a "systems thinking" approach to analyzing the core sub
processes within the overall process flow diagram. The appropriate view of each sub
process was a system with inputs, outputs and a context. This is shown in Figure 8.4.
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CONTEXT:
• Goals
• Critical Success Factors
OUTPUTS:
• Cost/Productivity
-"'Quality
• Time/Flexibility/Delivery
• Safety/Morale
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Figure 8.4: Systems Thinking: Each sub process has inputs, outputs and context
We characterize the inputs into each sub process in tenns of the 4 M's: Manpower,
Machines, Materials and Methods. Similarly, we characterize each sub process in tenns of
its outputs or its performance measures. These performance measures are
cost/productivity, quality, time/flexibility/delivery and safety/morale.
In addition, each sub process has a context which dictats its goals and critical
success factors. This information was mostly qualitative and was obtained though the
interviews.
8.4 Framework for Learning and Benchmarking
Systems thinking in term~ of the level of abstraction and inputs-outputs-context
structure allows us to expand the concept of the pharmaceutical manufacturing process flow
diagram to develop a framework for benchmarking. The framework shown in Figure 8.5
and depicts the one we intend to use for the benchmarking study. Using the value chain
analysis defined by Michael Porter value chain (Porter, 1985) is created by a number of
71
different activities. These are categorized as primary activities or secondary activities. The
process flow diagram represents the primary activities that are performed on the product.
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Figure 8.5: Framework for benchmarking
These primary activities are supported by the finn's infrastructure, technology
development, human resource management and procurement. A process can be a single
activity or a collection of activities. For pharmaceutical manufacturing, the primary
activities can be grouped in to five core manufacturing sub processes: inbound logistics,
active ingredient manufacture, bulk formulation, packaging and outbound logistics.
The flow of materials through several value added functions can be done in a single
plant but often is done at multiple sites within a single fully integrated finn or multiple sites
involving different companies. For this reason, we have chosen to develop and apply
benchmarking at the sub process level in order to facilitate comparison of similar activities
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on an intra- or inter-firm basis. The support activities into each sub process are the inputs.
Each sub process can then be evaluated in tenns of its outputs or measures of performance.
This framework also allows us to analyze different product types.
8.4 Core sub process quantitative questionnaire
The goal of the Pharmaceutical Industry Bencl1ll1arking Study was to analyze and
compare manufacturing effectiveness and efficiency within the pharmaceutical industry.
This questionnaire attempted to measure manufacturing petformance through a series of
qualitative and qU3.J,titative perlormance metrics. Data gathered in this questionnaire was
meant to be analyzed within the context of the company's mission, goals and critical
success factors.
The primary activities to pharmaceutical manufacturing are further grouped into
five sequential processes. These primary processes are inbound logistics, active ingredient
production, bulk product fonnulation, packaging and outbound logistics.
The first part of this questionnaire is subdivided into five sections. These sections
correspond to the five sequential primary processes. Within each section we attempt to
characterize the inputs (support activities) in term of manpower, materials, machines and
methods and the outputs (dimensions of performance) in terms of Cost /Productivity,
Quality, TimeIFlexibility/Service and SafetylMorale.
8.4.1 INBOUND LOGISTICS:
Inbound logistics involves activities associated with receiving, storing and
disseminating inputs to the product, such as material handling, warehousing, inventory
control, vehicle scheduling, returns to suppliers.
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Inbound logistics in a phannaceutical plants typically involves actually receiving the
material. This material is typically in inventory before the plant personnel then perform a
QC analysis on the materials to check for a match to specifications. The material is then
stored in the warehouse where it sits until it is required in the plant. Important detenninants
of the cost, quality, flexibility and morale of these operations depends on the number of
people involved, their experience levels, the kind of materials involved, the relationships
with the suppliers and the use of information technology. Figure 8.6 depicts some of
these input measures.
In addition, there are a number of components of performance. Important indicators of
performance are the levels of inventory, the fraction of lots that are approved, the times
taken for actual testing and release of the materials, the timeliness of the supplier deliveries,
the space layout in the warehouse and the safety and morale of the workforce.
8.4.2 ACTIVE INGREDIENT MANUFACTURE:
The active ingredient manufacturing process IS the one by which the
pharmacologically active chemical is manufactured in a pure form. This production process
can be through chemical manufacturing methods or through the use of biochemical
synthesis (e.g.. fetmentation or cell culture). The process includes both the production and
purification of the active ingredient.
Typically active ingredient manufacture involves a number of processing steps. In
addition, there are often a number of QC steps between the processing steps. In between
all of these steps there are opportunities for inventory to build up.
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Benchmarking the Inbound Logistics Process
OUTPUTS IMEASURES
• Cost/Productivity IAverage raw materials inventory level
INPUTS MEASURES
• People Number of people
Avg. experience of people
Education of people
• Materials Cost of materials purchased
Raw Materials
Consumable Supplies
• Methods Number of suppliers
Raw Materials
Consumable Supplies
Number of certified suppliers
Need to perform on-site QC
No need to perform on-sjte ac
Avg. length of supply contracts
Dollars spent on supplier training
Time to review a supplier
• Machines Use of Information Technology
• Quality
• Time/Flexibilityl
Service
• Safety/Morale
Vendor lots approved / Lots received
# of defective released lots/# of lots released
Avg. ac release time turnaround for materials
Average actual raw materials test time
Lead time between order placement & release
Average time the material sits in inventory
0/0 on-time deliveries from suppliers
Time operations had to ~Jait for materials
# of times operations had to wait
Average amt of waiting time
Floor Space dedicated to inbound logistics
Avg. distance traveled by raw materials
# of safety related incidents
# of safety related lost work days
# suggestions submitted by employees
# of ideas submitted that were implemented
Employee job absence rate
Emclovee turnover
Figure 8.6: Input and Output measures used to benchmark the inbound logistics process
Table 8.7 depicts the input and output measures used to benchmark the active
ingredient manufacturing process. Some of the important inputs into the process that have
a direct bearing on petformance include the number of people, their education and training
levels, the kind of materials, the number of complexity of the steps involved, the batch
sizes, number of products produced, the kind of equipment and the use of information
technology. Important components of petformance include the cost of the active ingredient
produced, the maintenance expenses, the number of lots that need to be rejected, reworked
or retested, the cycle time, capacity utilization, new product introductions, schedule
adherence and safety and worker morale.
8.4.3 BULK FORMULATION:
The bulk formulation process involves combining the bulk active ingredient with
inert substances like diluents or extenders. The mix is then manufactured into a finished
delivery fonn such as a pill, capsule, tablet, cream, or lotion.
Bulk formulation typically involves a fewer number of active ingredient steps than
active ingredient manufacturing. Table 8.8 depicts the input and output measures
associated with benchmarking the bulk formulation process. These metrics are quite
similar in nature to those described for the active ingredient Inanufacturing process.
8.4.4 PACKAGING:
Packaging is where the finished product is packaged into bottles or vials of various
sizes and/or dosage. This process also involves labeling and boxing. Packaging
processes typically involve a line flow. This is in contrast to most active ingredient
manufacturing and bulk formulation processing that is typically done in batches.
Packaging is also the least proprietary in nature.
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Benchmarking the Active Ingredient Manufacturing Process
INPUTS MEASURES
• People # of direct production employees
Maintenance employees
Experience of people
Education of people
• Materials Cost of materials used
• Methods # of proc. steps In act. ingred. mfg.
# of these steps outsourced?
# of steps using dedicated facilities
Produced year round?
Batch size
Lot size
# of batches/yr
Cumulative # of batches mfg. to date
Set-up time
Run time
Annual production
# of years of production
# of Inter-plant transfers
# of total clctive ingredients produced
Avg. involvement In work teams
'# people involved in "continuous improvement"
Fraction of time the workforce is idle
Avg weekly overtime hrs for employees
Average hours of training / Total work hours
Total # of people involved in ac and QA
• Machines Use of Information Technology
Plant value at construction/purchase
0/0 oper. budget used for equipment enhancements
Average age of active ingredient production equipment
Cost of capital assumed for equipment investments
OUTPUTS MEASURES
• Cost/Productivity Total cost of active ingredient produced
Production overhead cost
Maintenance expenses
Value of average work-in-process
Value of active ingredient inventories
Inventory holding cost
• QuaBty Lots mfg. right first time / Total lots mfg.
Ok of initiated lots that are:
I Rejected by mfg. (waste)Reprocessed by mfg.Rejected by QC/QA
Retested by aC/QA
# of 483 citations by FDA
Major
Minor
• Time/Flexibility/ # of new prods. introduced into mfg.
Service Avg. capacity utilization of facility
Annual operating hours
Annual hrs for prevo maintenance & turnovers
Annual hrs the equipment is idle
Degree of computer automation
New product ramp-up time
# of significant process-plant modifications
Trigger for process-plant modification:
External
Internal
'I Actual prodn. /forecast
• Safety/Morale # suggestions submitted employees
# of suggestions by maintenance employees
# of suggestions by aC/QA personnel
Total # of ideas implemented
Total # safety related incidents
Lost workday cases per 100 prod. employees
Employee job absence rate
Production employee turnover
Figure 8.7: Input and Output measures used to benchmark the active ingredient manufacturing process
Benchmarking the Bulk Formulation Process
INPUTS MEASURES
• People # of direct production employees
Maintenance employees
Experrence of people
Education of people
• Materials Cost of materials used
• Methods # of proc. steps In bulk formulation
# of these steps outsourced?
# of steps uSing dedicated facIlities
Produced year round?
Batch size
Lot size
# of batches/yr
Cumulative # of batches mfg. to date
Set-up time
Run time
Annual production
# of years of production
# of Inter-plant transfers
# of total bulk formulations produced
Avg. Involvement in work teams
# people Involved in "contlnuous improvemenf'
Fraction of time the workforce is idle
Avg weekly overtime hrs for employees
Average hours of training / Total work hours
Total # of people Involved In QC and QA
• Machines Use of Information Technology
Plant value at construction/purchase
0/0 oper. budget used for equipment enhancements
Average age of bulk formulation equipment
Cost of capital assumed for equipment investments
OUTPUTS MEASURES
• Cost/Productivity Total cost of bulk formutions produced
Production overhead cost
Maintenance expenses
Value of average work-in-process
Value of bulk formulation inventories
Inventory holding cost
• Quality Lots mfg. right first time / Total lots mfg.
% of initiated lots that are:
Rejected by mfg. (waste)
Reprocessed by mfg.
Rejected by aC/QA
Retested by aC/QA
# of 483 citations by FDA
Major
Minor
• Time/Flexibility/ # of new prods. introduced into bulk formlation
Service Avg. capacity utilization of facility
Annual operating hours
Annual hrs for prevo maintenance & turnovers
Annual hrs the equipment is idle
Degree of computer automation
New product ramp-up time
# of significant process-plant modifications
Trigger for process-plant modification:
External
Internal
Actual prodn. /forecast
• Safety/Mo rale # suggestions submitted employees
# of suggestions by maintenance employees
# of suggestions by aC/QA personnel
Total # of ideas implemented
Total # safety related incidents
Lost workday cases per 100 prod. employees
Employee job absence rate
Production employee turnover
Figure 8.8: Input and Output measures used to benchmark the bulk formulation process
Table 8.9 depicts the input and output measures used to benchmark the packaging
operation. These measure are quite similar to those used for bulk formulation and active
ingredient manufacture.
8.4e5 OUTBOUND LOGISTICS:
Outbound logistics involves activities that associated with collecting, storing and
physically distributing the product such as finished goods warehousing, material handling,
delivery vehicle operation, order processing, and scheduling.
Figure 8.10 shows the inputs and output measures used to benchmark the output
logistics process. Important components that determine the performance include the
number of people involved, their experience and education, the cost of goods sold, the
number of customers and the use of infonnation technology.
Relevant measures of performance include finished goods inven~ory levels~ the
number of customer complaints, the QC test tinle and release tin1e, the number of due dates
missed, the layout of the warehouse and safety and worker morale.
8.5 Results obtained from core sub process level benchmarking
8.5.1 Inbound Logistics
Table 8.1 depicts 10 columns of inbound logistics data from 4 different plants.
Bl, B2 and B4 are biotechnology plants while P6 is a brand name active ingredient
manufacturing plant.
Plant P6 has a larger number of people (direct and indirect) working on inbound
logistics. The biotechnology plants have people with higher levels of education. Plant P6,
on the other hand, purchases significantly larger value of total raw materials and
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Benchmarking the Packaging Process
INPUTS MEASURES
• People # of direct packaging employees
Maintenance employees
Experience of people
Education of people
• Materials Cost of materials used
o Methods # of proc. steps in packaging
# of these steps outsourced?
# of steps uSing dedicated facIlities
Produced year round?
Batch size
Lot size
# of batches/yr
Cumulative # of batches packaged to date
Set-up time
Run time
Annual production
# of years of production
# of inter-plant transfers
# of total packages producad
Avg. Involvement in work teams
# people involved in IIcontlnuous Improvement"
Fraction of time th,':l workforce IS idle
Avg weekly overtime hrs for employees
Average hours of training / Total work hours
Total # of people involved in ac and QA
• Machines Use of Information Technology
Plant value at construction/purchase
0/0 oper. budget used for equipment enhancements
Average age of packaging equipment
Cost of capital assumed for equipment investments
OUTPUTS MEASURES
• Cost/Productivity Total cost of packages produced
Production overhead cost
Maintenance expenses
Value of average work-in-process
Value of packaging inventories
Inventory holding cost
• Quality Lots mfg. right first time / Total lots mfg.
0/0 of Initiated lots that are:
Rejected by pkg. (waste)
Reprocessed by pkg.
Rejected by aC/QA
Retested by aC/QA
# of 483 citations by FDA
Major
Minor
• Time/Flexibility/ # of new prods. introduced into packaging
Service Avg. capacity utilization of facility
Annual operating hours
Annual hrs for prevo maintenance & turnovers
Annual h~s the equipment is idle
Degree of computer automation
New product ramp-up time
# of significant process-plant modifications
Trigger for process-plant modification:
External
Internal
Actual prodn. /forecast
• Safety/Mo rale # suggestions submitted employees
# of suggestions by maintenance employees
# of suggestions by QC/QA personnel
Total # of ideas implemented
Total # safety related incidents
Lost workday cases per 100 pkg. employees
Employee job absence rate
Pkg. employee turnover
Figure 8.9: Input and Output measures used to benchmark the packaging process
Benchmarking the Outbound Logistics Process
OUTPUTS IMEASURES
• Cost/Productivity IAverage finished goods inventory level
INPUTS MEASURES
• People Number of people
Avg. experience of people
Education of people
• Materials Cost of materials sold
• Methods Number of customers
Avg. length of contracts
$ spent on customer service training
Time to switch customers
• Machines Use of Information Technology
• Quality
Q Time/Flexibility/
Service
• Safety/Morale
Total complaints / Number of units
Avg. ac release time turnaround for fin. goods
Average length of ac hold on fin. goods
Average actual finished goods test time
Due dates missed / Total deliveries
Lead time between delivery & order placement
Avg. time the finished good sits in inventory
Total Floor Space
Avg. distance traveled by fin. goods
# of safety related incidents
# of safety related lost work days
# suggestions submitted by employees
# of ideas submitted that were implemented
Employee job absence rate
Emolovee turnover
Figure 8.10: Input and Output measures used to benchmark the outbound logistics process
Table 8.1: Inbound logistics data
nNm en>lIJN1I]) IL,(Q)<GH!1rlI«:S BI-92 81·93 82·92 82..93 B4..92 84..93 P6-90 P6·91 P6..92 P6·93
lINIflU'Il'Sa
lJeople # people (direct) 0.33 0.33 0.67 0.67 11.5 13.5 6 4 4 4
# people (inJirect) 0.25 0.25 0.25 0.25 2.25 2.25 4 4 4 4
Yrs of service in field 10 10 10 10 10 10 13 11 12 13
Education (BS) 3 3 0 0 0 0
Education (MSIMBA) 1.75 1.75 0 0 0 0
Education (PhD) 0 0 0 0 0 0
Education (High School/other) All All All All 9 11 0 0 0 0
Materials Cost of purchased RM (million) 0.9 0.9 4.6 4.6 1.0 2.7 39.3 28.3 19.7 25.3
Cost of purchased consumables (mill) 0.1 0.1 0.1 0.1 0.1 0.3 4.8 3.9 4.5 3.9
Methods # of suppliers (raw materials) 10 10 12 12 63 66 48 3S 28 28
# of suppliers (consumable supplies) 6 6 6 6 - 25 21 21 19
# of certified suppliers (on-site QC) 10 10 12 12 63 66 0 0 1 1
# of certified suppliers (no on-site QC) 0 0 0 0 0 0 0 0 0 0
Avg. length of supply contracts (yrs) 1 1 1 1 6 6 1 1 1 1
Dollars spent on supplier training 0 0 0 0 0 0 0 0 0 0
Time to review a supplier (wks) 8 8 8 8 0 0 2 3 5 5
Machines Use of Info. Tech 0.5 0.5 0.5 0.5 2 2 1 2 2 2
<0>lU'll'lfo>llJ'Il'S ~
CostJProductivity Avg. raw materials inventory level 12 4 12 4 86 48 2.7 4 3 1.8
Quality # of vendor lots approvedllots received 990Je N/A N/A 99.20o/c 98.30OJe
# of defective released lot~lIots released 3% - 0% 0%
TimeiFlexibUity/Service Avg. QC release tIme for RM (hrs) 240 N/A N/A 18 7
Avg. QC lest time for RM NID - - - -
Time bet. order placement & release (wks) - - -
Avg. time material sits in inventory (wks) 4 4 4 4 - 3.1 3 2.9
0/0 on-time deliveries from suppliers 96% 960/0 96% 96% 90% 78% 78% 85% 85%
# times operations waited for materials 0 0 0 3 2.5 2,.5 - - -
Avg. amount of waiting time (days) 0 0 0 2 hrs 0.5 0.5 - - -
Roor space for inbound logistics (sq. ft) 2000 2000 3000 3000 8707 8707 46,000 46,000 46,000 46,000
Avg. distance travelled by RM after receipt 150 150 150 150 400 400 1,000 1,000 1,000 1,000
Safety/Morale # safety related incidents in inoound logistics 0 0 - 2 0 0 1
# of safety related lost work days 0 0 - 1 0 0 a
# of suggestions by employees 100 100 - - 20 25 0 0 0 0
# of submitted ideas implemented 50 SO - - 13 17 0 0 0 0
Employee job absentee rate 4% 40/0 - - 12% 24% 4% 4% 4% 40/0
Employee turnover in inbound logistics 1% 10/0 - - 10% 6% 0 15% 0 0
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consumables. Plants P6 and B4 have a significantly larger number of suppliers than B 1
and B2. However, P6 is seems to be consistently redu~ing the number of its suppliers and
is beginning to certify them. P6 is now taking a longer time to review a new supplier.
While the on-time deliveries are relatively low for plant P6, they are improving. Similarly
plant P6 is improving in terms of safety while the job absentee rate is dropping. Overall,
plant P6 seems to be improving the way it does inbound logistics.
Plant B4, on the other hand, with its high raw material inventory levels and large
number of suppliers have a high employee absentee and turnover rate. The suggestion
mechanism is improving.
8.5.2 Active Ingredient Manufacture
Table 8.2 shows 6 columns of active ingredient manufacturing data from two
different plants. B4 represents ~ biotechnology plant while P6 represents a brand name
active ingredient manufacturing plant. P6 started off with a significantly larger number of
production employees but the number is seen to be dropping while the numbers for B4 are
increasing. The biotechnology plant is seen to have a higher educated workforce.
There is are more processing steps involved in the biotechnology process. In
addition all the steps involve dedicated facilities. The batch sizes for the biotechnology
process are significantly higher, the set-up times significantly longer and the number of
products significantly lower. The biotechnology plants involves a significant number of
interplant transfers.
The active ingredient plant P6 uses a lot more overtime hours while the
biotechnology plant does more total training. The number people involved in active
ingredient QC is comparable. This number is going up in the case of plant P6.
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The brand-name active ingredient plant produces higher total value active ingredient
that the biotechnology plant and has higher overhead expenses. Maintenance expenses are
comparable. The waste levels in the active ingredient production plant of P6 depict no
clear trend. It is surprising to note that biotechnology plant B4 retests as much as 100% of
its QC lots. Plant B4 also operates its plants for a fewer number of hours during the year.
Plant B4 indicates a higher number of lots produced and a higher number rejected.
The dedicated biotechnology plant is run considerably fewer hours than the plant
P6. Plant B4 also involves a larger number of process-plant modifications. Plant P6
actually equals or exceeds its initially scheduled production requirements. The absentee
rate is higher for plant P6. Plant P6 also seems to had a large layoff in 1991.
8.5.3 Bulk ~~ormulation
Table 8.3 depicts 4 columns of bulk fonnulation data all collected from the same
plant P6 over multiple years. The table indicates that there have not been significant
changes in the number of direct production or maintenance employees. Bulk fOITIlulation,
here involves only one process step. There is no change in the batch size, or the set up
time or run time of the bulk fonnulation step.
The % of waste in dropped significantly in tlJe plant P6. This is because of the focus in
plant P6 on waste levels.
8.5.4 Packaging
Table 8.4 depicts the packaging data for plant P6. The columns indicate that
packaging is represented as being one processing step. Most of the products are produced
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Table 8.2: Active Inaredient manufacturinR data
ACTIVB INGRBD MANUFACTURB 84-92 84-93 P6-90 P6-91 P6-92 P6-93
INPUTS
Manpower # of direct prodn. employees 33 78 103 57 57 53
# Maintenance employees 3 3 NA 13 8 7
Education (BS) 35 6 7 7 7
Education (MSIMBA) 3 0 0 0 0
Education (PhD) 0 0 0 0 0
Education (High School/Other) 40 0
°
0 0
Method # of process steps 7 7 4,2,1 NA,2,1 NA,2,1 NA,2,1
# of these steps outsourced? 0 0 0,0,0 NA,O,O NA,O,O NA,O,O
# of steps using dedicated facilities 7 7 4,2,0 NA,2,0 NA,2,0 NA,2,0
Produced year round? N Y Y,Y,Y NA,Y,Y NA,Y,Y N;\. Y,Y
Batch size (liters) 7500 7500 180,45,30 NA,45,30 NA,45,30 NA,182,30
# of batches/yr 1800,950,59 NA, 1000,50 NA,980,59 NA,200,60
Cumulative # of batches mfg. to date 23 86
Set-up time (hrs) 88 174 24,48,48 NA,24,48 NA,24,48 NA,48,48
Annual prodn. 72 72 350,44,1.8 NA,45,1.5 NA,45,1.8 NA,43,1.8
# of inter·plant transfers 4 5 0,0,0 NA,O,O NA,O,O NA,O,O
# total active ingredients produced 1 1 8 8 8 --g
Involvement in work teams (1-5) 1 2.5 1 1 2 2
# people in cont. improvement (direct) 17 0 3 7 12
# people in cont. improvement (indirect) 5
°
24 61 100
%f time the workforce is idle 0 0
°
0 0 0
Wkly overtime hr for employees 5 592 601 617 586
Avg. hrs of training/total wk hrs. 15%
Hrs of training/wk hrs (FDA stipulated) 0.240/0 0.49% 0.46% 0.43%
Hrs of training/wk hrs (On job training) 0.160/0 0.260/0 0.26% 0.27o/D
Hrs of tra-ninglwk hrs (off job training) NA NA NA NA
Avg. hrs trainicglw0rk hrs ~other) 0.29% 0.330/0 0.33% 0.57%
# people in active ingred. QC 30 35 37 42 42
M2chlnes Plant value at construction/purchase (M) 8.1 28.5 22.7 25.0 27.8
0/0 oper. budget for equipt. improvrnnts NID 20.20% 57.30% 28.50% 73%
Age of prodn. equipraellt (yrs) 4 5 5.7 6.2 5.8 5.9
01t1'II'IIDlU'll'S
CostJProductivity Cost of active ingredient produced (M) 11.0 14.8 46.4 72.6 48.9 46.4
Production overhead cost 9.4 10.9 16.0 14.4 15.6 19.3
Maintenance expenses 1.2 1.2 1.3 1.1 1.1 0.9
Value active ingred. inventory held (m) 11.9 12.7 14.3 4.9 4.7 4.6
Perception of inventory holding cost 180/0 180/0 NA NA NA NA
Quality Lots nght first time!fotallots mfg. 96.65% 94.800/0 98.050/0 97.850/0
Discard Rate (waste) 3.350/0 5.20% 1.95% 2.150/0
TolLlllots scheduled for production 23 86
Total lots unsuccessfuUy mfg. 0 4
Total lots released by QC. 22 63
Total lots rejected by QA 1 19
Total lots retested by QC l00o/c 1000/0
# of 483 citations (major) 6 1 2 0
# of 483 dtations (minor) N/A 3 1 0 0 0
rrinlelFlexJService # new active ingred. introduced 0 0 0 0 0 0
Annual operating hrs of facility 3600 3600 6900 5900 5900 5600
lIrs reqd. for prev. maint. & turnovers 800 800 NA 320 961.25 759.5
Annual hrs the equipment is idle 4400 0 96 21iS 216 48
Degree of computer automation 4 4 1 1 1 3
New product ramp-up time N/A NA NA NA NA
# significant process-plant modificatIons 3 3 0 0 3 1
Actual prodn./forecasted reqUIrements 1120/0 lOOo/~ 1210/0 1060/0 1260/0
SafetylMoraie # suggestIons by prodn employees N/A 0 0 0 2
# suggestions by maintenance employees N/A 0 0 0 2
# suggestions by QC/QA personnel N/A 0 0
°
0
Total # of Ideas subnutted implemented 0 0 0 0
# of safety related incidenL~ 19 16 9 10
Lost workday cases/l 00 prod employees 0 1.25 4.2 3.3
Prod. employee job absence rale 2%? 4% 4% 4% 40/0
Prod. employee turnover 10%? 00/0 440/0 0% 0%
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Table 8.3: Bulk formulation data
BULK. FORMULATION P6-9O P6·91 P6·92 P6·93
INPUTS
Manpower # of direct prodn. employees 4 5 5 5
# of Maintenance employees NA 1 2 2
Education (BS) 0 0 0 0
Education (MSIMBA) 0
°
0 0
Education (PhD)
°
0 0 0
Education (High School/other)
°
0
°
0
Method # of process steps in bulk formulation 1,1,1 1,1.1 1,1,1 1.1,1
# of these steps outsourced? 0,0,0 0,0,0 0,0,0 090,0
# of steps using dedicated facilities 0,0,0 0,0,0 0,0,0 0,0,0
Produced year round? Y Y Y Y
Batch size 315,275,74 315,275,74 315,275,74 315,275,74
# of batches/yr 104,9,39 109,10,18 110,7,6 105,18,1
Cumulative # of batches mfg. to date
Set-up time (hrs) 8,8/8 8,8,8 8,8,8 8,8,8
Runwtime (hrs) 10,10,10 10,10,10 10,10,10 10,10,10
Annual prodn. 33,2.5,2.9 34,2.7,1.4 35,1.9.0.5 33,3.1,0.08
# of yrs. of pradn.
# of inter-plant transfers 0,0,0 0,0,0 0,0.0 0,0.0
# total bulk formulations produced? 5 5 4 5
Involvement in work teams 1 1 1 2
# of people in continuous improvement (direct) 0 0 0 1
# of people in continuous improvement (indirect) 0 0 0 1
Fraction of time the workforce is idle 0
°
0 0
Wkly overtime hr for bulk formulation employees 19 34 22 19
Hrs of trainingltotal work hrs (FDA stipulated) 0.19% 0.46% 0.450/0 0.43%
Hrs of training/total work hrs (On the jcb training) 0.630/0 0.52% 0.630/0 0.540/0
Hrs of training/total work hrs (other training) 0.310/0 0.23% 0.360/0 0.420/0
# of people involved in QC and QA 47 50 56 54
OlU'Il'IPTU'II'§
~ostJProduct1vity Cost of bulk formulations produced (aol1ual) (m) 27.49 51.42 31.16 30.6
Production overhead cost 11.26 2.23 14.14 15.82
Maintenance expenses 0.19 0.21 0.18 0.17
Total value of avg. bulk formulation inventory held 2.57 3.09 1.07 1.04
Ruality Lots right the frrst timeffotallots mfg. 890/0 98.500/0 98.50% 98.800/0
Discard Rate 11% 1.50% 1.50% 1.50%
# of 483 citations (major) 2 3 0 0
# of 483 citations (minor) 0 0 0 0
TimeJFjexibUity/Service # of new bulk formulations introduced into mfg. 0 0 0 0
Annual operating hrs of facility 760 685 615 620
Hrs required for prevo maine and turnovers NA ]26.1 51 62
Annual hrs the equipment is idle 7056 7527 7653 7520
Degree of computer automation 1 1 1 1
New product ramp-up time NA NA NA NA
# of significant process-plant modifications 0 0 0 0
Trigger for process-plant modifications (external) 0 0 0 0
Trigger for process-plant modifications (internal) 0 0 0 0
Actual prodn.lAggregate forecast requirements 100% 950/0 87% 101%
$afetylMorale # of suggestions by bulk formulation employees 0 0 0 1
# of suggestions by maintenance employees 0 0 0 0
# of suggestions submitted by QC.lQA personnel 0 0 0 0
Total # of ideas submitted that were implemented a 0 0 0
Total # of safety related incidents 0 2 0 1
Lost wor~day cases/I 00 bulk formulation employees 0 0
°
40
Bulk formulation employee job absence rate 40/0 40/0 40/0 40/0
Bulk formulation employee turnover 0 0 0 0
year round with batch sizes that did not change. However, the number of ratches made
each year does change.
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The number of packagings made has reduced and the work involved in teams and
continuous improvement projects has gone up. The number of people in QC and QA has
increased. A smaller percentage of the operating budget was being spent on equipment
improvement.
The cost of the packaging material went up slightly and so did the packaging
overhead cost. Maintenance expenses seem to have dropped. The waste levels are
showing an overall downward trend in packaging as well. However, the facility is being
operated for fewer hours and kept idle for longer times.
8.5.5 Outbound Logistics
Table 8.5 depicts 10 columns of outbound logistics data from 4 different plants.
Bl, B2 and B4 represent biotechnology plants while P6 represents a brand name active
ingredient manufacturing plant. As shown, the brand name active ingredient plant has a
significantly larger number of people involved in inbound logistics both directly and
indirectly. Most of the individuals working in inbound logistics have a number of years of
experience. They are slightly more educated in the case of the biotechnology plants.
Similarly, the cost of m::Lterials sold are significantly larger in the case of the active
ingredient manufacturing plant. Plants Bland B4 have a long contract length. Bland B2
perceive themselves as being more automated than the others.
The biotechnology plants hold a significantly larger amount of finished goods
inventory. However, plants Bland 84 are decreasing their inventory levels. Plant B4 still
has a particularly high finished goods inventory level. Plant B4 has an abnormally high
number of customer complaints in 1993. In addition, plant 84 has a srnaller fraction of
employee suggestions implemented and the highest job absentee rate. Plants Bland B2
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Table 8.4: Packaaiofi( data
PACKAGING P6-90 P6-91 P6-92 P6-93
INPUTS
Manpower # of direct prodn. employees in packaging 80 78 78 76
Maintenance employees in packaging NA 9 7 6
Education (BS) 18 20 20 20
Education (MSIMBA) 0
°
0 0
Education (PhD) 0 0 0
°Education (High School/Other) 0 0 0
°Method # of process steps in packaging 1,1,1 1,1.1 1,1,1 1,1,1
# of these steps outsuurced? 0,0,0 0,0,0 0,0,0 0,0,0
# of steps using dedicated facilities 0.0,0 0,0,0 0,0,0 0,0,0
Produced year round? Y Y Y Y
Batch size 35.14.5,38 35,14.5,38 35,14.5,38 35,14.5,38
# of batches/yr 245,234,96 225,125,101 229,48,115 217,51,115
Set-up time (hrs) 4,4,24 4,4,24 4,4,24 4,4,24
Run time (hrs) 12.12,12 12,12,12 12,12,12 12,12,12
Annual prodo. 8560;3386;3650 7877;1819;3852 8021 ;698;4390 7591 ;734;4382
# of inter-plant transfers 0
°
0 0
'# total packagings are produced? 41 41 30 33
Involvement in work teams 1 1 1 2
# people in cont. improvement (direct) 0 3 3 3
# people in cont. improvement (indirect) 0 8 8 8
% time the workforce is idle 0 0 0 0
Weekly overtime he 293 195 236 231
Hrs training/work hrs (FDA stipulated) 0.180/0 0.41% 0.450/0 0.50%
Hrs training/work hrs (On the job training) 0.430/0 0.43% 0.390/0 0.37%
Hrs training/work hrs (off the job training) NA NA NA NA
Hrs training/work hrs (other training) 0.37% 0.23% 0.36% 0.50%
Total # of people involved in QC and QA 47 50 56 54
Machines Plant value at construction/purchase (m) 13.47 13.49 13.68 14.44
0/0 oper. budget for eqpmt. irnprovemnts. 14.60% 10.70% 7.20% 6.10%
Avg. a~e of packaging equipment 5.7 6.6 7.1 6.8
@1UTIPlIJ-n'~
CostIProductivity Cost of packagings produced (annual) 36.4 39.34 39.87 41.94
Packaging overhead cost 16.02 23.18 25.07 26.74
Maintenance expenses 0.87 0.91 0.81 0.66
Total value of avg. WIP NA NA NA NA
Value of avg. packaging. ittventory held 3.25 6.79 5.51 4.66
~uallty Lots right first timeITotallots mfg. 87"0 93.60% 97.900/0 96.30%
Discard rate for packaging (waste) 13tro 6..40% 2.100/0 3.700/0
# of 483 citations (major) 0 0 3 0
# of 483 citations (minor) 0 0
°
0
rrlmeIFJexlServJce # of new prods introduced into packaging 0 0 0 0
Annual operating hrs of facihty 2300 1784 1568 1532
Hrs reqd for prevent. maint. & turnovers NA 3320 2003 2020
Hrs the equipment is idle 4t66 5432 5503 S664
Degree of computer automation 2 2 3 3
New product ramp-up time NA NA NA NA
# significant process-plant modifications 0 0
°
0
Actual prodn.lforecastcd requirements 100% 99OJo 87'Yc 950/c
SafetylMoraJe # suggestions by packaging employees 0 0 0 5
# suggestions by maintenance employees 0 0 2 2
# of suggestions by QC./QA personnel 0 0 0 0
# ideas submitted implemented 0 0 2 5
# of safety related !Dcidents in packaging 51 16 14 29
Lost workday casesll 00 pack. employees 16 10.7 6.2 7.3
Packaging employee; JO absence rate 4C7'() 40/0 40/0 40/0
PackagIng employee turnover 0 20/0 20/0 29'c
on the other hand, have an abnormally high employee turnover in outbound logistics of
100%. This is probably because the results are skewed by the very small number of people
involved.
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Table 8.5: Outbound I02istics data
OUTBOUND LOGISTICS 81-92 81-93 B2-92 82-93 84-92 84-93 P6-90 P6-91 P6-92 P6-93
lIN:fllJTg,
People # people (direct) 0 0.33 0.33 0.33 1.5 1.5 6 4 4 4
# people (indirect) 0.25 0.25 3 2 2 2
Yrs of service in field 10 10 10 10 13 11 12 13
Education (BS) - - - - 0 0 0 0 0 0
Education (MSIMBA) - - - 0.75 0.75 0 0 0 0
Education (PhD) - - - 0 0 0 0 0 0
Education (High School/other) All All All All 1 1 0 0 0 0
Materials Cost of materials sold (M) 0.755 0.692 7.8 12.1 9.687 19.622 86.34 66.41 52.71 57.53
Methods # of customers 4 4 400 600 1 1 5 5 5 5
Length of contracL~ (yrs) 10 10 NA NA 15 14 NA NA NA NA
$ spent on customer service training (M) 0.5 0.5 2 2 0 0 0 0 0 0
Time to switch customers (wks) NA NA NA NA N/A N/A 0 0 0 0
Machines Use of Info. Tech (1 to";) 3 3 3 3 1 1 1 2 2 2
(C U':I':PlIJ'!I'~ I
CosUProductlvity Finished gcods inventory (wks) 8 6 30 30 60 41 7 7 7 7
Quality Total complaints!# of umts 00/0 24%
Timt1.~exibility!Service QC finished goods release tIme (hrs) 30 days 60 days - 115 NA 456 408 528
Avg. test time for finished goods (hrs) 600 - 115 NA NA NA NA
Length of QC hold on finished goods (hrs) 0 30 days - 150 510 182 182 350 350
Time bet. delivery & order placement (wks) < lday < Iday < Iday < 1day 12 12 12 12
Time finished goods sits in inventory (wks) 8 8 4 4 60 41 12 10 8 7
Floor space for outbound logistics (sq. ft) 1000 1000 2000 2000 1655 46.000 46,000 46,000 46,000
Distance travelled by Finished goods (ft) 150 150 150 150 400 3,000 3,000 3,000 3,000
Safety/~loraJe # of safety related Incidenl~ 0 0 0 0 1 1 0 0
## of safety related lost work days 0 0 0 0 1 0 0 0
# of suggestions submi tted 25 25 25 25 10 0 0 1 2
# of ideas submitted implemented 25 25 25 25 5 0 0 1 2
Employee job absentee rate 0% 00/0 00/0 0% 50/0 4tro 40/0 3% 3%
Employee tur'10ver 0% 1000/0 00/0 100% N/A 0 33% 00/0 0%
It is useful to note that the brand name active ingredient manufacturing plant P6 has
been reducing its finished goods inventory over the last four years. The number of safety
related incidents and lost work days are down and the number of ideas submitted al1d
implemented are up. Similarly, its job absentee rate is slowly going down. Hence, along
some dimensions P6 is showing significant continuous improvement.
8.6 Evaluation of core sub process benchmarking approach
The verdict is not yet out. More benchmarking data is still coming in from plants.
However, in the meantime benchmarking the core manufacturing sub processes has given
us some valuable insights into the perfonnance of each of the plants. It is possible to look
at each of the metrics and highlight the highs and lows. We think that this can be valuable
information for each of the plants involved in the study. For many of them, it is not clear,
as to where they stand relative to other plants within the industry. Clearly every plant is
different. Each plant differs in its history, its strategy, product and process technology, its
organizational structure and culture. Hence, there \\t°ill always be reasons why the numbers
need (0 be different for the different plants. The goal of the benchmarking study is to
provide a rigorous means to understanding the sources of the variability. We think that
the core manufacturing sub process approach provides a framework to identify the sources
of variability in a manner that is based on the activities of the manufacturing process by
analyzing the process horizontally across the value chain rather that vertically along
functional lines. Within this framework all the functions are focused on the value chain
and the process flow diagram as a means to be able to manage the supply chain in order to
be able to ultimately provide custoJner satisfaction. This is the more appropriate structure
for learning.
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Chapter 9
Overall Results and Discussion
9.1 Learning disabilities of the pharmaceutical manufacturing organization
While each of the companies we worked with believed that manufacturing was
going to become increasingly important, many did not envision the possible role that
manufacturing could playas a competitive weapon. While assigned stages is always
somewhat arbitrary, most pharmaceutical plants seemed to belong to Stages 1 and 2
according to Wheelwright's classification (Wheelwright, 1985). Many are in the process
of moving from Stage 1 to 2 and trying to establish parity with other plants in the industry.
However, most did not envision pharmaceutical manufacturing moving into Stages 3 or 4.
In their minds manufacturing still continued to be second to R&D and marketing.
Manufacturing was typically reacting to choices made in R&D and marketing.
Manufacturing was not seen as being a competitive weapon.
Even thougt. most pharmaceutical companies believe that manufacturing is
becoming increasingly important, most pharmaceutical organization continue to have a
defensive mindset about change in manufacturing. This is because the mindset about
manufacturing is slow to change (Martin, 1993). There are many good reasons for the
conservative frame of mind of phannaceutical organizations towards manufacturing. Some
of them include the large cost of making a mistake in terms of FDA and regulatory
requirements and the fact that most of their products make it into the human body. There is
also a large return from innovative R&D that results in novel therapeutic benefit. Hence,
the mind set has been to focus on reseClfch and have a defensive strategy towards
manufacturing.
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We argue that this defensive mindset leads to a set of defensive routines within the
organization that hinder learning. As a result many pharmaceutical manufacturing
organizations suffer from many of the well known learning disabilities (Senge, 1990).
This is evidenced by their defensive mindset towards manufacturing. This mindset is
reinforced by the view towards manufacturing of the rest of the organization. The
defensive routines are also evidenced by the structural and infrastructural choices that the
organization makes. The defensive mindset shows up in structural choices about capacity,
facilities, technologies and vertical integration and in the infrastrural choices about vendors,
new products, human resources, quality and systems.
One of the biggest baniers to change is the pharmaceutical companies prior success.
Given the drastic change in the industry structure, there is a need for a appropriate
innovative response (Hammer, 1993). A number of companies within our sample are
beginning to respond.
9.2 Benchmarking provides a rigorous basis for organizational learning
We thInk that benchmarking can provide a means to catalyze organizaitional change
within pharmaceutical manufacturing. The fu·st step is to change the organizational mindset
from being functional to be based on the process flow diagram or value chain. This is the
framework for organizational learning through benchmarking.
Benchmarking data obtained in both the functional fonn and the core manufacturing
process form show considerable variability along many dimensions among the plants that
have been investigated. The variability should be used as a means to drive the creative team
problem solving ability of the phannaceutical manufacturing organization. This process of
understanding the sources of the variability can be used to drive the organizationalleaming
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process. Organizational learning may be the only real source of sustainable competitive
advantage (Strata, 89)
9.3 Role of accounting systems
Most pharmaceutical manufacturing plants still rely heavily on traditional cost
accounting techniques where only a few cost drivers are identified and overhead is typically
allocated on the basis is direct labor, machine hours and floor space. This made it quite
difficult for many of the plants to fill out our questionnaire because it did not always fit into
their organizational structure and available accounting information (Kaplan, 1988). There
has been tremendous resistance to moving towards a more activity based costing system
(Donlon, et al., 1992). Most personnel within the plant believe that an activity based cost
system is not worth the effort. Once again, we believe that this is because they are
underestimating the benefit that can be obtained from an accurate co~ting system (Keegan et
aI., 1989). Poor accounting information and the lack of petformance measures hinder
organizational learning (Mcilhattan, 1987). A few of the pharmaceutical companies are
now beginning to move in that direction.
9.4 Supply chain analysis of value chain.
A number of phannaceutical companies are beginning to focus on their relationships
with suppliers. For example, plant P6 has focused on its relationships with its suppliers
and has begun to make progress towards reducing the number of suppliers and developing
a closer relationship with a few certified suppliers. Similarly a number of companies are
focusing in their customer service levels.
9.5 Cost of Quality
To measure components of the cost of quality, we measured the amount of product
that incurs additional costs during processing. Such cost can result from retesting,
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excessive inventory hold, reworking, scrap, etc. This parameter was not measured in the
plants examined. Further, it was difficult to arrive at a consensus on what the number was
and how it could be determined from available records.
Preliminary analysis suggests tllat a significant amount of material produced incurs
some additional cost because of something not done correctly the first time. We believe
this estimate is conservative. Table 9.1 shows Juran's framework for assessing the cost of
quality.
In most pharmaceutical plants quality is typically defined in terms of compliance.
Hence, most pharmaceutical plants had a large number of QC and QA personnel. We
believe that quality has typically been inspected in. Given Juran's framework, we
speculate that the internal failure costs are too high in order to keep the external failure costs
down. We argue that most pharmaceutical plants must focus on decreasing internal failure
costs. In addition, given the tendency to inspect in quality we suspect that the appraisal
costs are very high. We argue that the pharmaceutical plants must focus instead on
prevention and building quality into the process rather than having to inspect it in.
9.6 Inventory Management: Just-in-time?
None of the plants we investigated practiced the concepts of just-in-time
manufacturing. None of them believe that the concepts of just-in-time manufacturing were
applicable to the pharmaceutical industry. Once, again we argue that this is because they
are not thinking about JIT in terms of the philosophy. Rather JIT is still simply viewed as
being a reduction in inventory.
We argue that this is because they under-estimate the cost of holding inventory.
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Table 9.1: Juran's Categories of Quality Costs
INTERNAL FAILURE COSTS: costs from product defects before shipment 10 the customer.
Scrap - net losses in labor and material resulting from defective goods that cannot econoolically
be repaired or used.
Rework - costs of correcting defective products to make them usable.
Retest - costs of reinspection and retesting of products that have been reworked.
Downtime - costs of idle facilities, equipment, and labor due to defective products.
Yield losses - costs of process yields lower that could be attained through improved process
control.
Disposition - the time of those involved in determining whether non conforming products are
usable and what should be done with them.
EXTERNAL F AlLURE COSTS: costs associated with defects found after shipment to
customer.
Complaint adjustment - costs of investigating and responding to complaints due to defective
products, faulty installation, or improper instructions to users.
Returned material - costs associated with receiving and replacing defective products returned
from the field.
Warranty charges • costs of services and repairs perfonned under warranty contracts.
Allowances - income losses due to downgrading products for sale as SeC(;~j3 and to concessions
made to customers who accept substandard products as is.
APPRAISAL COSTS: costs associated with discovering the condition of producls and raw
materials.
Incoming ",aterial inspection - costs associated with detennining the quality of vendors'
products.
Inspection and test - costs of checking product conformance through design and manufacture,
including tests dOlJe on customers' premises.
Maintaining accuracy of test equipment • costs of operating and maintaining measuring
instruments.
Materials and services consumed· costs of products consumed in c1estructive tests; also
materials and services (e.g. electric power) consumed in testing.
Evaluation of stocks - costs of testing products in storage
PREVENTION COSTS: costs associated lvith preventing defects and limiting failure and
appraisal costs.
Quality planning - costs of creating and communicating plans and data systems for quality,
inspection, reliability, and related activities - includes the costs of preparing all necessary manuals
and procedures.
NeK· products review - costs of preparing bid proposals, evaluating new designs, preparing
test and experim~ntai programs, and related quality activities associated with launching new
products.
Training - costs of developing and conducting training programs aimed at improving quality
perfonnance.
Process Control - costs of process control aimed at achieving fitness for use, as distinguished
frOITi productivity (a difficult distinction to make in practice)
Quality data acquisition and analysis • cost of operating the quality data system to get
continuing data on quality perfonnance.
Quality reporting - costs of bringing together and presenting quality data to upper
management.
Improvement projects - cost of buildin~ and implementin~ breakthrou~h proiects.
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Most plants viewed the cost of holding inventory as being the prevailing interest rate.
However, this is not the case. Inventory is just a symptom of bigger problems. The cost
of holding excess inventory is significantly higher because it is a symptom of an
organization that is not fixing the underlying sources of the variability but rather buffering
itself against it. Inventory hides more expensive problems.
Within the framework on the economic order quantity (EOQ) model (McClain et al.,
1992) we argue that the pharmaceutical manufacturing organization is overestimating the
benefits of economies of scale and underestimating the ability to reduce set up costs.
Rather than really building in the flexibility into the manufacturing system but
reducing manufacturing cycle times and reducing set up times (Blackburn, 1991), many
pharmaceutical companies simply build in flexibility by holding excess finished goods
inventory. Once again, this is an example when the organization is dominated by the
marketing atm of the organization which rather than building in flexibility into the
manufacturing organization simply avoids doing that by holding excess inventory.
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Chapter 10
Future work
The story is far from over. Benchmarking and learning are continuous on-going
processes. There are many directions to go from here.
1. Consistency Analysis:
While the data obtained so far has been quite insightful there is no way to check the
accuracy of the data that has been obtained. The data may not represent reality because of
many reasons including the difficulty in understanding its definition, inaccurate data with
the plant itself or the need to make inaccurate approximation. Hence an important next step
would be to ensure the accuracy of the data itself.
2. Additional metrics:
It is unlikely that we have already discovered the luost representative set of
perlormance metrics. Metrics defining and refining is a constant process. There will need
to be significant additions and subtractions to the existing set of perfonnance measures.
3. Level of Analysis:
It is still unclear as to what the appropriate level of analysis is. This depends on
the kinds of questions that are trying to be answered and the amount of resources available.
A next step may be to go down to lower level of analysis. This decision needs to be made
in collaboration with the lead benchmarking partner companies.
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4. Flow of Information:
Our focus so far has been on the flow of materials as represented by the process
flow diagram and the value chain. A similar analysis can be made on the flow of
infolTIlation through the organization.
5. Structural issues:
This study has focused more on infrastructural issues within a plant rather than
interaction between plants themselves. Analysis of plant networks could be done at a
higher level of analysis. This is particularly important in the context of the recent trend
toward rationalizing phannaceutical plants throughout the world (Keene et al., 1990).
6. Multi-company workshop:
There has been considerable interest in getting our lead benchmarking partners
together with representatives from other plants in multi-company workshop where they can
discuss metrics and the results in a more collaborative manner.
7. Interactions between R&D and marketing:
Another importance manufacturing petformance issue is the nature of interaction
and coordination between R&D and manufacturing and manufacturing and marketing.
8. Impact of regulation:
The existing study can be considerably enhanced by being able to measure the
impact of regulalton on phannaceutical manufacturing.
9. "Best-in-class" benchmarking:
All the existing plants are from within the phannaceutical industry. A significant
additional benefit can be derived by extending this analysis to plants outside the industry.
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That would significantly increase the chances of obtained innovative "best-practice"
solutions.
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Chapter 12
Memorable quotes
Change management:
All truth goes through three steps:
First it is ridiculed, second it is violently opposed and finally it is accepted as self-evident. -- Gennan
philosopher, Arthur Schopenhauer.
We are what we think. All that we are arises with aUf thoughts. With our thoughts, we make our world.
-- The Buddha
Man is not the creature of circumstance; circumstances are the creations of men. -- Benjamin Disraeli.
Things do not change; we change. -- Henry David Thoreau.
When written in Chinese, the word tcrisis' is composed of two characters - one represents danger, and the
other represents opportunity. -- John F. Kennedy.
We all know how Adam said to Eve: liMy dear, we live in a period of transition." -- Vida D. Schudder, The
Privilege of Age.
Benchmarking:
Ask and you will receive. Seek and you will find; knock, and it will be opened to you. -- Matthew 7:7.
The important thing is not to stop questioning. Curiosity has its own reason for eyjsting. One cannot
belp but be in awe when he contemplates the mysteries of eternity ~ of life, of the marvelous structure of
reality. It is enough if one hies merely to comprehend a little of this mystery every day. Never Jose a holy
curiosity. -- Albert Einstein.
If we all did things we are capable of doing, we would astound ourselves. -- Thomas A. Ed;son.
The knowledge of the world is only to be acquired in the world, and not in a closet. -- Lord Chesterfield.
Learning:
Experience is not what happens to a man; it is what a man does with what happens to him. -- Aldous
Huxley.
He who asks questions cannot avoid the answers. -- Cameroon Proverb.
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Men are wise in proportion, not to their experience, but to their capacity for experience. -- George Bernard
Shaw.
Wealth is the product of man's capacity to think. -- Ayn Rand.
As the world becomes more interconnected and business becomes more complex and dynamic, work must
become more IIlearningful". It is no longer sufficient to have one person leaming for the organization, a
Ford or a Sloan or a Watson. Its just not possible any longer to "figure it out" from the top, and have
everyone else following lhe order of the "grand strategist tl • The organizations that will truly excel in the
future will be the organizations that discover how to tap people's conunitment and capacity to learn at all
levels in an organization. Peter M. Senge.
We can do it:
I know of no more encouraging fact than the unquestionable ability of man to elevate his life by a
conscious endeavor. Henry David Thoreau.
Ask questions:
Take away the cause, and the effect ceases. -- Miguel De Cervantes.
Life is painting a picture, not doing a sum. -- Oliver Wendell Holmes, Jr.
An perception of truth is the detection of an analogy. - Henry David Thoreau.
There can be no transfonning of darkness into light and of apathy into movement without emotion. -- Carl
lung.
Nothing happens unless first a dream. -- Carl Sandburg.
We are what and where we are because we have rrrst imagined it. -- Donald Curtis.
We frrst make our habits, and then our habits make us. -- John Dryden.
Hold yourself responsible for a higher standard than anybody else expects of you. -- Henry Ward Beecher.
ManIs mind stretc~led to a new idea never goes back to its arigina! dimensions. -- Oliver Wendell Holmes.
We lift ourselves by our thought we climb upon our vision of ourselves. -- Orison Swett Marden.
The best effect of fine persons is felt after we have left their presence. -- Ralph Walda Emerson.
We have time enough if we will but use it aright. -- Johann Wolfgang Von Goethe.
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A mighty flame followeth a tiny spark. -- Dante.
Every man is an impossibility until he is born. -- Raplh Waldo Emerson.
We should have no regrets. We should never look back. The past in finished. There is nothing to be
gained by going over it. Whatever it gave us in the experiences it brought us was something we bad to
know. -- Rebecca Beard, Everyman's search.
I had six honest serving men; they taught lne all I knew. Their names were where and what and when and
why and how and who. -- Rudyard Kipling.
The most effective way to ensure the value of the future is confront the present courageously and
constructively. -- Rollo May, Manis Search for Himself.
Three helping one another will do as much as six men singly. -- Spanish Proverb.
A conclusion is the place where you got tired of thinking. Martin H. Fischer.
The fatal tendency of mankind to leave off thinking about a thing when it is no longer doubtful, is the
cause of half of their errors. John Stuart Mill.
For of course, the true meaning of a tenn is to be found by observing what a man does with it, not by what
be says about it. P. W. Bridgman.
Reality is pretty brutal, pretty filthy, when you conte to grips with it. Yet it's glorious all the same. Ifs
so real and satisfactory. -- George Bernard Shaw, Fanny's First Play.
Never cease to be convinced that life might be better - your own and other's. -- Andre Gide, The Fruits of
the Earth.
The only things that evolve by themselves in an organization are disorder, friction, and malperfonnance.
Peter Drucker.
The toughest thing about success is that you've got to keep on being a success. -- Irving Berlin.
The great thing in this world is not so much where we are, but in what direction we are moving. -- Oliver
Wendell Holmes.
Man blames fate for other accidents, but feels personally responsible when he makes a hole in one.
Horizons magazine.
To profess to have an aim and then to neglect the means of its execution is self-delusion of the most
dangerous sort. -- John Dewey.
105
Very often a change of self is needed more than a cbange of scene. -- A. C. Benson.
Words:
All the fun's in how you say a thing. -- Robert Frost.
Questionnaires:
It is a capital mistake to theorize before one has data. Insensibly one begins to twist facts to suit theories,
instead of theories to fit facts. Sir Pu1:hur Conan Coyle - ~he adventures of Sherlock Holmes "Scandal in
Bohemia".
"What gets measured gets done" has never been so powerful a truth. -- Tom Peters, Thriving on Chaos.
To treat your facts with imagination is one thing, but to imagine your facts is another. -- John Burroughs.
Statistics is the art of lying by means of figures. Dr. Wilhelm Stekhel.
Learning:
While information may be infinite, the ways of structuring are not.. . You choice will be determined by the
story you want to tell. -- Richard Saul Wunnan.
Learning is not a task or a problem - it is a 'Nay to be in the world. Man learns as he pursues goals and
projects that have meaning for him. -- Sidney Jourard.
We are not troubled by things, but by the opinions which we have of things. -- Epictetus.
Learning can be defined as the process of remembering what you are interested in. -- Richard Saul Wunnan.
Questions are the creative acts of intelligence. -- Frank Kingdom.
l'ell me, I'll forget. Show me, I may remember. But involve me and I'll understand. -- Chinese Proverb.
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Appendix A
Functional Benchmarking Questionnaire
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MIT Program on the Pharmaceutical Industry
Industry Benchmarkillg Project
Performance Measures Survey
Revision: 2/07/93
Instructions:
The purpose of this survey is to analyze and compare the manufacturing operations of fums
within the phannaceutical industry. The questions attempt to establish a set of measures
that characterize the petformance of a manufacturing business. To best capture this, each
production facility or plant site must complete its own survey.
Each plant should be treated as an individual business. For example, a plant's raw
materials consist of raw materials and intemlediates purchased from external sources and
intermediates "purchased" (or transferred) from internal sources, i.e. other plants. A
plant's finished products are both final goods that will be sold to external sources or
intermediates that will be "sold" (or transferred) to other intel11al plants.
This survey has been divided into the following six (6) categories:
Human Resource Management (HRM)
Financial (FIN)
Production (PROD)
Quality Assurance/Operations (QA)
Materials ManagementIHandling (MM)
Miscellaneous (MISe)
All questions should be answered in strict compliance with the definitions given. Any
qualifications should be noted, referencing the sUlVey category and question number.
All infonnation should come from 1990, 1991, and 1992 operating data unless otherwise
specified. Data should be recorded by year and by type of production facility (i.e. bulk
chemical manufacturing or phannaceutical manufacturing). If a plant site has both chemical
and phannaceutical capabilities and these operations are physically linked by continuous
production then this plant can complete one (1) sUlVey. However if the operations are
separated by inventory (over 2 weeks) then treat them as separate facilities.
Where data on top 5 products is requested, the top 5 products are detennined by the highest
dollar sales per year (units produced per year x final or transfer price per unit).
Company:
Name of Facility:
Location of Facility:
Type of Facility:
Age of Facility:
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Human Resource Management (HRM)
Measure
1) Total nuniber of direct plant production employees
Employees includes only salaned and hourly personnel in the following categories:
1) Direct production employees and supervisors (Exclude administration and maintenance).
2) QC personal and supervisors involved in raw material. production. dnd finishe.d goods testing
3) Employees directly involved in material management and handhng
2) Production employees / Total number of employees
Production employees are all employees directly associated with manufacturing as defined above in question #1.
Total employees is total plant population.
3) Maintenance employees / Production employees
Maintenance employees include all equipment maintenance personnel but exclude buildings and ground personnel.
4) Production employee turnover
Number of separations I Average number employees on payroll
Turnover figures cover all permanent separations. whether voluntary or involuntary.
This does not include employees placed on temporary layoff or retirements.
5) Lost workday cases per 100 employees
Total number of lost workdays I [number of employees I IOOJ
Production employees only as defined above in question #!.
6) Production employee job absence rate
Number of worker-days lost through absence I Total number of worker days
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7) What percent of employees are involved in work teams
Production employees only as defined in #1.
Human Resource Management (HRM) (continued)
Measure
8) Average weekly overtime hours for production employees
Average number of weekly overtime hours worked by production employees only.
9) Average hours of training / Total work hours
Production employees only
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Financial (FIN)
Measure
1) Production overhead cost / Total cost of finished goods
Total cost of finished goods includes direct materiaJs, direct labor, and overhead.
2) Maintenance expenses / Total cost of finished goods
Maintenance expenses defined as total expenses in repairs and il"1provements for production buildings and equipment.
Total cost of finished goods includes direct materials, direct labor, and overhead.
3) Sales / Number of production employees
Sales are total gross revenues derived from external sales or inter:lal transfers.
Production employees are defined in HRM Section, Question #1
4) Total value of average raw material inventories held
Include all raw materials and intermediate goods received from internal or external sources.
Exclude all bulk packaging material and utilities (ie. nitrogen. hydrogen, sterile 'Water, etc).
5) Total value of average work-in-process
This includes all material in process and excludes raw material inventory or finished goods inventory.
6) Total value of average finished goods inventories held
Include all finished goods and intermediate goods ready for shipment to internal or external customers.
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7) Typical inventory holding cost
Expressed as a percent.
FinanCkll (FIN) (continued)
Measure
8) Total cost of finished goods / Total cost of goods bought
See FIN question #1 for definition of cost of finished goods.
Finished goods can be intermediates transferred to another internal plant.
Cost of goods bought are all raw materials and intermediates purchased from external sources or internal plants.
9) Plant value at time of construction or purchase
10) Year plant was operational or year purchased
11) Discount rate used on plant value
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Production (PROD)
Measure
1) Are your production operations operating on Just-In-Time
2) How many total products are produced
Products are either finished goods or intermediates that will be transferred or sold to internal or external custon "'"
3) How many products use dedicated facilities
4) How many products in #3 above are produced year-round
Continuous operations. excluding required maintenance and scheduled clean-outs.
5) Total number of lots manufactured on site
This includes all lots manufactured for all products at the site. both for internal plant transfer or external sales.
6) Lots manufactured right frrst time I Total lots manufactured
Lots right frrst time are lots not rejected, retested, reinspected or reprocessed.
Product reprocessed before total process completion is counted not manufactured right 1st time.
AdditIonal testing required that is outside of normal practice is counted not manufactured right 1st time.
Lots held pending further testing or approval are counted as not manufactured right 1st time.
7) Average total resident cycle time for top 5 products
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Resident cycle time starts with receipt of all raw materials and ends with final QC approval and delivery to internal or external customers.
Top 5 products are determined by total yearly dollar sales to internal or external customers.
Production (PROD) (continued)
Measure
8) Average raw materials inventory level for top 5 products
Measured in production weeks
For the top 5 finished products by sales as defined above in PROD question #7.
9) Average time required for facility turnover between products
Average setup ti me measured in total hours (includes clean-outs, re-piping, and test runs).
10) Average number of inter-plant transfers for top 5 products
How many internal transfers does the product experience before its sold to an external customer.
11) Discard rate for fetmentation operations
Number of batches discarded for any reason over total number of batches produced
12) Number of new products introduced into manufacturing
13) Average age of equipment used in process for top 5 products
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14) Average capacity utilization of facility
Exclude turnover periods or required preventive maintenance.
Production (PROD) (continued)
Measur~
15) Average capacity utilization of manpower
Is there a degree of underemployment of production employees.
16) Degree of automation
On a scale of (1) to (5) rate L'1e degree of automation for the site with (1) being mostly manual and (5) being mostly automated.
17) New product ramp-up time
If a new product was introduced. how long (in weeks) was it before the fITst two consecutive batches were manufactured right the fITst time.
Refer to question #6 for definition of manufactured right 1st time.
18) Total number of lots manufactured to date for top 5 products
Measured at year end
19) Avg number of years top 5 products have been produced at plant
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Quality Assurance/Operations (QA)
Measure
1) Total complaints / Number of units
Total complaints include "customer" and FDA complaints.
"Customer" includes any user (interncl or external) of finished or intermediate goods
Units measured as 1 Kilo for Bulk Chern, 100 tablets for tablets and one container for all other
If a customer complaint is made against an entire 10 Kilo delivery, this counts as 10 complaints
2) Number of vendor lots aiJproved / Numbti' of lots received
This includes all raw materials and intermediates supplied by external sources.
Lots being held pending further QC tests are counted as not approved.
3) Average QC: release time turnaround for raw materials
Measured in hours. from the time materials arrive at plant to the time QC officially releases material for production use
Includes intermediates received from other plants
4) Average QC release time turnaround for finished goods
Measured in hours, from the time goods are completed to the time QC officially releases goods for shipment or sale
5) Average length of QC hold on finished goods
The average time (in days) finished goods are held in storage by QC because of potential abnormalities
6) Average actual raw materials test time
Average actual test run-time, measured in hours.
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7) Average actual finished goods test time
Average actual test run-time. measured in hours.
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Materials Management/Handling (MM)
Measure
1) Number of due dates missed / Total number of deliveries
Deliveries are to the "customer" (ie. phannaceutical manufacturer. next chemical plant. stock, or marketing)
This includes internal or external customers.
Partial shipments are considered missed due dates.
Renegotiated shipping dates are considered missed due date.
2) Finished goods stock I Total inventory
Finished goods stock as a percent of total inventory
3) Work-In-Process I Total inventory
WIP as a percent of total inventory
4) Percentage of on-time deliveries from suppliers
On-time deliveries are complete usable orders (partial deliveries are not on~time)
Materials received out of specification or held for further testing are considered not on-time
Suppliers are outside vendors and inter~plant transfers
5) Total number of suppliers for top 5 material inputs purchased
Includes only raw materials and intermediates purchased from external sources.
Top 5 inputs determined by total dollar value purchased for the year.
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Miscellaneous (MISe)
Measure
1) Number of suggestions submitted by production employees
Any work place or process related suggestions.
Definition of production employees in HRM Section. Question #1.
2) Number of suggestions submitted by maintenance employees
Any work place or process related suggestio.J.
Include salaried and hourly employees. bu: exclude management and administration.
3) Total number of ideas submitted that were implemented
From questions #1 and #2 above.
4) Actual sales I Aggregate forecast requirements for top 5 products
Actual sales are the actual Kilos taken by customer at year end (external or internal customers)
Forecast are the initial production requirements at the beginning of production year (measured in Kilos)
5) Number of personnel dedicated to continuous process improvement
Breakdown by degree: # B.S.
#M.S.
# Ph.D.
# Other
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6) Number of significant process-plant modifications
Significant defined as requiring revalidation, FDA approval, or factory shutdown in excess of 1 production week. Excludes product turnover.
7) Trigger for process-plant modification:
External (FDA, EPA, Customer, etc.)
Internal (ideas submitted, continuous improvement, QC, etc.)
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Appendix B
Core manufacturing process benchmarking questionnaire
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PERFORMANCE MEASURES QUESTIONNAIRE
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Company:
Name of Facility:
Location of Facility:
Primary Contact Person:
Title:
Date:
Copyright @ Massachusetts Institute of Technology, 1994.
Please return the completed questionnaire to:
G. K. Raju,
Project Coordinator,
Pharmaceutical Industry Benchmarking Project,
MIT Room 16-011,
Massachusetts Institute ofTechnology,
Cambridge, MA 02139.
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Goal:
The goal of the Pharmaceutical Industry Benchmarking Study is to analyze and compare manufacturing
effectiveness and efficiency within the pharmaceutical industry. This questionnaire attempts to measure
manufacturing performance through a series of qualitative and quantitative performance metrics. Data
gathered in this questionnaire will be analyzed within the context of the company's mission, goals and
critical success factors.
Framework for benchmarking questionnaire:
As, shown in the "framework for benchmarking" figure below, manufacturing operations are viewed as
involving a set of primary and support activities. Primary activities are the activities involved in the
physical creation of the product and its sale. Support activities support the primary activities by providing
the material, manpower, machines and methods.
Framework for Benchmarking
_t.\c1-~~('q.~r--------------------------""'"
SUPPORTt----_r--,'EeRRMmn~EaJ1'lll~I'I'FRRro1~IQ'D'1l'RmR!mI1m_-_r-__1
ACTIVITIE:lI-----------:H~U~M .....AN~R::"='ESO~U~RC::"='E.....M.....AN--A--GE~M::"='ENT~--T"""'"--------I
PROCUREMENT( ATERIALS MANAGEMENT)
PRIMARY
ACTIVITIE
Active Ingredient "anufaotJ. Bulk Product Formulation I Packaging I
1110\7_8\7
... ,' , ,., ' , , ' .. , , .
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PERFORMANCE· .
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2;·. QuiiiIUY.:· .•:.>: ••··:.:: •••:.: •••••: ••. :.:.: ••::.::
~;.·rim~I~~!d~~~j~"'1···· .
. 4.SahltYJMOr..t.<·· ..
The primary activities to pharmaceutical manufacturing are further grouped into five sequential processes.
These primary processes are inbound logistics, active ingredient production, bulk product formulation,
packaging and outbound logistics.
The first part of this questionnaire is subdivided into five sections. These sections correspond to the five
sequential primary processes. Within each section we attempt to characterize the inputs (support
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activities) in teffil of manpower, materials, machines and methods and the outputs (dimensions of
petfonnance) in terms of Cost /Productivity, Quality, TimelFlexibility/Service and Safety/Morale.
Other comments about the questionnaire:
• Each production facility or plant site must complete its own questionnaire. Each plant
should be treated as an individual business. For example, a plant's raw materials consist of raw
materials and intermediates purchased from external sources and intermediates "purchased" (or
transferred) from internal sources, i.e. other plants. A plant's finished products are both final goods
that will be sold to external sources or intennediates that will be "sold" (or transferred) to other internal
plants. Data should be recorded by year and by type of production facility (i.e. bulk chemical
manufacturing or pharmaceutical manufacturing). If a plant site has multiple manufacturing capabilities
and these operations are physically linked little or no inventory held in between then this plant can
complete one (1) survey. However if the operations are separated by inventory then treat them as
separate facilities.
• All questions should be answered in strict compliance with the definitions given.
Any qualifications should be noted, referencing the survey category and question number.
• All information should come from 1990, 1991, 1992 and 1993 operating data unless
otherwise specified.
Confidentiality:
• Both the questionnaire and the data are confidential. The company specific details will
remain confidential. Only normalized and aggregate information will be reported in an overall
manner. In addition, you will be given an opportunity to review results prior to any publication.
Please treat this questionnaire as being a confidential document.
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INBOUND LOGISTICS:
Inbound logistics involves activities associated with receiving, storing and disseminating inputs to the
product, such as material handling, warehousing, inventory control, vehicle scheduling, returns to
suppliers.
MEASURE:
Inputs Into Inbound Loeistics Process:
People
Number of people involved in inbound logistics
Direct
Indirect
Avg. experience of people involved in inbound logistics
Years of service (i.e. experience in field).
1990 1991 1992 1993
Education of people
Breakdown by degree: #BS.
#M.S./MBA
# Ph.D.
# High School/Other
Materials
Cost of materials purchased
Raw Materials (Includes intermediates purchased from external sources) _
Consumable Supplies
Methods
Number of suppliers
Raw Materials (Includes intermediates purchased from external sources) _
Consumable Supplies
Number of certified suppliers
Need to perfonn on-site QC of incoming material
Do not need to petform on-site QC
Average length of supply contracts
Dollars spent on supplier training
Supplier training in JIT1 quality control etc.
Time to review a supplier (vendor qualification time in weeks)
Machines
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Use of Infonnation Technology (Scale of 1 to 5)
e.g.. 1 indicates Manual system, 2 a frrst generation MRP system,
5 indicates electronic data interchange with suppliers.
Performance or Inbound LOlistics Process;
Cost/Pr,rJductivity:
Average raw materials inventoI)' level
Measured m producbon weeks
Quality:
Number of vendor lots approved I Number of lots received
This includes all raw malenala ilJ.:d mtermedlatea supphed by external sources
Lou being held pending futtber QC rests are coumed as DOl approved
# l1f defective released lots/# of lots released
Time/FlexibilityIService:
Average QC release time turnaround for raw materials
Measured m bourse from the tune matenals amve at plant 10 the tIme QC officIally releases matenal for product
o usc Includes mtermedultes received from other plzants
Average actual raw materials test time
Average ac:tualat run~timc, measured m hours
Lead time between order placement and release (in weeks)
Average time the material sits in inventory (in weeks)
Percentage of on-time deliveries from suppliers
On~tllne dehvenea are complete usable orders (partIal dehvenes are not em-nm:)
Macenals fec:Clvcd out of speclficabon or held for further testing are consIdered oot on-tunc:
Supphcrc are octslde vendors and lItter-plant tnnsfers
Total time that operations has had to wait to get materials
# of times operations had to wait
Average amt of waiting time
Total Floor Space dedicated to inbound logistics (sq. ft)
Average distance traveled by raw m.aterials after receipt (ft)
Safety/Morale:
# of safety related incidents in inbound logistics
# of safety related lost work days
# suggestions submitted by employees in inbound logisti~s
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Any work place or process related suggestIons
# of ideas submitted that were implemented
From queibODS *1 and *2 .bow
Employee job absence rate in inbound logistics
Number of worker-days losl through abeence I Total number of worker days
Employee turnover in inbound logistics
Number of ICparabODJ I AYeraAc number cmployees on payroll
Turnover figure. cover all permanenl separabons. whether voluntary or lDyolunlaty
TIDs doet nol lDclude employees placed on temporary layoff or retuements
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ACTIVE INGREDIENT MANUFACTURE:
This is the process in which the phannacologically active chemical is manufactured in a pure form. This
production process can be through chemical manufacturing methods or through the use of biochemical
synthesis (e.g.. fermentation or cell culture). The process includes both the production and purification of
the active ingredient.
MEASURE:
Inputs Into Actiye Ineredient Manufacture:
Manpower:
# of direct production employees in active ingredient prodn.
Employees includes only salaried and hourly personnel in the following categories.
1) Direct production employees and supervisors (Exclude admi nistration and maintenance).
2) QC personal lind supervisors involved in active ingred. production
3) Employees directly involved 10 material management and ha.ndling in prodn.
Maintenance employees related to active ingredient prodo.
1990 1991 1992 1993
Ml1lllenanCC employees mclude all equJpmenr mamtenancc ~rsonnel but e~cludc hUlldmgs and ground personnel
Material:
Method:
The following table attempts to capture some the methods employed by your finn in manufacturing the
active ingredient. Please attach relevant process flow diagrams when possible. If you manufacture more
than three active ingredients please add in the necessary extra columns to the table below.
Inputs to Activ2 Ingredient I I02redient II I02redieot ill
I02redient Manufacture 1990 1991 1992 1993 1990 1991 1992 1993 1990 1991 1992 1993
# of proc. steps in act. ingred. mfg.
# of these steps outsourced?
# of steps using dedicated facilities
Produced year round?
Batch size
Lot size
..
# of batcbes/vr
Cumulative # of batches mfg. to date
Set-up time (hrs)
RUD time (hrs)
Annual production
# of years of production
# of inter-plant transfers
How many total active ingredients are produced
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Products IIJ'C' eather flDlsbed gocxts or Intermedlate! that wIll be tnnaferred or sold to mternal or eXlrmal customers
Average involvement of employees in work teams (Sca1eof 1·5)
1 indicates that all work is done individually 5 indicates that all work IS done an teams.
Education of people
Breakdown by degree: #B.S.
# M.S./MBA
# Ph.D.
# High SchooVOther
# people involved in "continuous improvement"
Direct
Indirect
Fraction of time the workforce is idle
Expressed as a percentage
Avg weekly overtime hrs for active ingred prod employees
Averase number of weekly overtlme hours worked by productIon employees only
~-----~-----~----~~----~-----------~-~-­-----------~-------~-----~--------~-----
Average hours of training / Total work hours (act. ingred. prodo employees)
FDA stipulated training
On the job training
Off the job training
Other training
Total # of people involved in active ingredient QC and QA
Machines:
Plant value at time of construction or purchase
% yrly operating budget used for equipnlent enhancements
Average age of active ingredient production equipment
Cost of capital assumed in making equipment investments
Performance of Active Ioa:redient Manufacture:
CostlProductivity
Total cost of active ingredient produced (annual)
Total cost of active ingredient includes direct materials, direct labor, and overhead.
Production overhead cost
Maintenance expenses
Mamtenance expenaes defined as total expenses 10 repairs and IDlprovemelUs for production b1l1dmgs and eqwpment
Total value of average work-in-process
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Th. mciude. aU malenal U1 procep aDd exclude. Ill'" DlalenaJ IDvcmory or fuuahcd goods lDVCDtory
-----------~----~~--------------------~~ - ~ -- ~ ~~
Total value of average active ingredient inventories held
Include aU fuuabed goods and JOlennedllb: goods ready for .lupment to Internal ex extemel customeR
What do you perceive as your inventory holding cost?
Expreaed u • perc~nt coat of capilal
------~-------~-------~----~--~~~----~-~--------~-~-~---~-----~---------~---
Quality
Lots manufactured right first time / Total lots manufactured
LOll n&ht fint tune are loti DOC rejected. rerelled. reullpecaed or reproct'ued
Product reproceaa:d before total procell ,omplebon 11 counted not manufactured ngh~ 1st umr
AddlbooaJ telun, reqUIred that Ie ouwde of Donnal prach« II counted not manuf.cnl~d right ] It ume
LOls held pendmg furtl¥r leJb~ or approval are counted as nO! manufactured "PIt ht bme
Percentage of initiated lots that are:
Rejected by active ingred. manufacturing (waste)
Reprocessed by active ingred. manufacturing
Rejected by WQA
Retested by QC/QA
# of 483 citations by FDA related to active ingred. mfg
Major
Minor
Time/Flexibility/Service
Number of new active ingredients introduced into mfg.
Average capacity utilization of facility
Annual operating hours
Annual hrs reqdfor preventative maintenance & turnovers
Annual hrs the equipment is idle
Degree of computer automation
On a scale of (1) to (5) rate the degree of automation for the site with (1) being mostly manual and (5)
being mostly automated Le. CIM.
New product ramp-up time
If II DeW product was mtroduoed. how long (m weeks) was It before the first two consecutl ve batches
were manufactured nglu the first b.me
Number of significant process-plant modifications
Slgmficant defined as requinng revahdabon. FDA approval. or factory shutdown m excess of I production week.
Excludes product turnover
Trigger for process-plant modification:
External (FDA, EPA, Customer, etc.)
Internal (ideas submitted, continuous jmprovement, QC, etc.)
Actual prodn. I Aggregate forecast requirements
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Actual prodn of active ingredient (Kgs) at year end (external or internal customers)
Forecast are th~ initial production requirements at the beginning of production year (Kgs)
~--------------~---~---------------~--­- ~ ~ ~- ~ - -
Safety/Morale:
# suggestions submitted by active ingred. prodn employees
Any ...Oft pliO: or proceu ~lared IUg,UbOIU
---~-----~-----~---~-----~------~--------- .. .- -- ---~-~_-.-.-.-_----~ -. __ ...._-- . -. .-_ --
# of suggestions submitted by maintenance employees
Any -art place or process rclared Iugestlon.
Include ..Jailed and hourly employee., but clclude managemenl and adnurultrlhon
--~---~-----------------~---------~--~----.,..----- ---.~-- --- --_.-.--..- ---.....---------
# of suggestions submitted by QC/QA personnel
Any -ext p~ or prooeu related lugelbon
----------------~----~----------------~~~ - ~~ - ~ ~ -
Total number of ideas submitted that were implemented
~-------------------------------~------­~ ~~~ ~ ~~ -~ -
Total # safety related incidents during active ingred. prod.
Lost workday cases per 100 active ingred prod. employees
Total number of Jost workdays I [nwnber of employees I 100]
Active ingredient production employee job absence rate
Number of worer-days lost through absence I TolBl number of worker days
Active ingredient production employee turnover
Number of seperaaoDS I A\'erage number employees 00 payroll
Turnover figures cover all permanent separatlons, wbell....r voluntary or mvoluntary
This does Dol mclude employees placed on temporary layoff or retlIemenlS
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BULK FORMULATION:
This process involves combining the bulk active ingredient with inert substances like diluent'i or extenders.
The mix is then manufactured into a finished delivery fonn such as a piil, capsule, tablet, cream, or lotion.
MEASURE:
IOlnts into bulk (ormulation:
Manpower:
# direct production employees in bulk fonnulation prodn.
Employees meludes only salaned and hourly pt"rSonnel In the followJng categones.
1) Direct production emp!oycetl And supervisors <Exclude adnuD1~trat~on and mamtenance)
2) QC personal and supervisors Invo!ved in bulk production testing
:\) Employees directly Involved in material management and handhng 1n bulk prodn
Maintenance employees related to bulk fOffilulation prodn.
1990 1991 1992 1993
Mamtcnan~ employees mclude all equipment maintenance p:rsorurl hut exclude bulldmg!! and ground personnel
Material:
Method:
The following table attempts to capture some the methods employed by your firm in manufacturing the
bulk product Please attach relevant process flow diagrams when possible. If you manufacture more than
three bulk fonnulations please add in the necessary extra columns to the table below.
Inputs to Bulk Bulk Formulation I Bulk Formulation II Bulk Formulation In
Formulation 1990 1991 1992 1993 1990 1991 1992 1993 1990 1991 1992 1993
# of proc. steps in buik formul mfg.
# of these steps outsourced?
# of steps using dedicated facili tles
Produced year round?
Batch size
Lot size
# of batches/yr
Cumulative # of batches mfg. to date
Set-up time (ms)
Run time (hrs)
Annual production
# of years of production
# of inter-plant transfers
How many total bulk fonnulations are produced
Products are ather fimsbed goods or mtermed1ates tbar Will be transferred or sold to IDtemal or external custOlIlC:fS
Average involvement of employees in work teams (Scale of 1-5)
1 indicates that all work is done individually. 5 indicates that all work is done in teams.
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Education of people
Breakdown by degree: #B.8.
#M.S./MBA
# Ph.D.
# High School/Other
# peopie involved in continuous process improvement
Direct
Indirect
Fraction of time the workforce is idle
Expressed as a percentage
Avg weekly overtime hrs for bulk fonnul. prodn employees _
Aver.,e nwnber of weekly ovcnune houn worked by produf;llon employees only
Average hours of training / Tota! work hours (bulk formuJ. prodn employecs)
FDA stipulated training
On the job training
Off the job training
Other training
Total # of people involved in bulk fannul. QC and QA
Machines:
Plant value at time of construction or purchase
% yrly operating budget used for equipment enhancements
Average age of bulk fonn production equipment
Cost of capital assumed in making equipment investments
Performance or bulk formulation:
Cost/Productivity
Total cost of bulk formul. produced
Total cost of bulk formuln. includes direct materials, drrect labor, and overhead.
Production overhead cost
Maintenance expenses
Mamtenanoe expeDJeS defmed as total expenses lO r~pll1rs and lUlprovements for producllon buddmgs and eqUIpment
Total value of average bulk fonnulation work-in-process
TIna includes all malenal m process UX; excludes raw matcnal lOventory or fImshcd goods mventory
Total value of average bulk fonnulation inventories held
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1Dctuck .u rlJU.bed loads and mtermedaate ,oods reDdy for lltupmenl Co internal .... eXlemal ..:ustomers
What do you perceive as being your inventory holding cost? _
Expreated u • percent co..r of capttal
Quality
Lots manufactured right first time / Total lots manufactured
Loti nghc fiut bme are lola not reJecled, rClC!lled, rell1."pe~lCd OJ reproccsacd
Producc Jeprocclled before cocal proceu completIOn III ("ounted not tnanufactu~d fllthl hi laDle
AddrIJonal feltIDg rrquared thai IS OUr.lde of normal praCUtt 15 counted nol manufactured fight lsi Ilmr
Loe. held pends~ funber le'bog or approval an: ~oWlled u noc rmnufl..:tured ng111 lat time
Percentage of initiated lots that are:
Rejected by bulk formulation (waste)
Reprocessed by bulk manufacturing
Rejected by (yJQA
Retested by ~/QA
# of 483 citations by FDA related to bulk fonnulation
Major
Minor
Time/FlexibilityIService
Number of new fotnlulations introduced into mfg
Average capacity utilization of bulk fonnulation facility
Annual operating hours
Annual hrs reqd for preventative maintenance & turnovers
Annual hrs the equipment is idle
Degree of computer automation in bulk fonnulation
On a scale of (1) to (5) rate the degree of automation for the site with (1) being mostly
manual and (5) being mostly automated Le. CIM.
New product ramp-up time for bulk fonnulation
If a DeW product was mttoduc:ed. how long (m weeks) was It before the flfSt two conseCUtive batches
were manufactured ngh1 the first tune.
Number of significant process-plant modifications
Slgm6cant defmed as requtring tevahdatlon, FDA approval, or factory shutdown m excess of 1 productlon week
Excludca product turnover.
Trigger for process-plant modification:
External (FDA, EPA, Customer, etc.)
Internal (ideas submitted, continuous improvement, QC, etc.)
Actual prodn. / Aggregate forecast requirements
Actual prodn of active ingredient (Kgs) at year end (external or internal customers)
Forecast are the initial production requirements at the beginning of production year (Kgs)
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Safety/Morale:
# suggestions submitted by bulk fonnuln prodn employees
# suggestions made by bulk fonnuI. maintenance employees _
Any wort place or prlXeu related lulQte.tlOn
Indude ..lalled and hourly employees. but e ..c1udc man.[l.emenl lnd .dnuruAtribon
# suggestions made by bulk fonnulation QC/QA personnel
Any work place or proce" related luuesllon
Total number of ideas submitted that were implemented
Total # safety related incidents related to bulk formul. prod.
Lost workday cases per 100 bulk formul. prode employees
Toql number of loat workdays I (number of employocs I 1GOI
Bulk fonnulation production employee job absence rate
Number of ....orur·day. IOSl through at.ence I Total number of worker dey.
Bulk fonnulation production employee turnover
Number of ICparaUOns I Awmlge number employ.:es 00 payroll
Turnover figures cover aU pcnnanent seplll1Jboru. whether voluntary or lDvoluntary
TtD. doea DOl mclude employees placed on temporary layoff or reluements
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PACKAGING:
The fmished product is packaged into bottles or vials of various sizes and/or dosage. This process also
involves labeling and boxing.
MEASURE;
Inputs into packaKioK:
Manpower:
# of direct production enlployees in packaging
Employees Include' only SlWled and hourly ~rsonnel In the fonowmg catcgcr:c!l
1) Duect production employees and supervIsors (Exclude adnumsttabOl1 lind mamten.mcc)
2) QC penonal and luperv1Scn Involved 10 producbon testing
3) Employees duccrly involved In l1UItenaJ m2lmgement and handhng 10 prodn
Maintenance employees related to packaging
1990 1991 1992 1993
Mamtcnance employees mclude all eqUIpment mamler.ance personnel oUl exclude bulldmgs and ground personnel
Material:
Method:
The following table attempts to capture some the methods employed by your finn in packaging. Please
attach relevant process flow diagrams when possible. If you manufacture more than three final package
types then please add in the necessary extra columns to the table below.
Inputs to Packagin2 FiD8i Package I Final Packa2e II Final Package III
Process 1990 1991 1992 1993 1990 1991 1992 1993 1990 1991 1992 1993
# of proc. steps in packa~ing
# of these steps outsourced?
# of steps using dedicated facilities
Produced year round?
Batch size
Lot size
# of batches/yr
Cumulative # of batches mfg. to date
Set-up time (hrs)
Run time (hrs)
Annual production
# of years of production
# of inter-plant transfers
How many total fmal package types are produced
Products are either fimabed goods or mtennedilltes that wIll be transferred or sold to mtemal ex' extemal customers
Avg involvement of employees in work teams (Scale of 1 to 5)
1 indicates that all work is done individually. 5 indicates that all work is done in teams.
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Education of people
Breakdown by degree: # B.S.
# M.S.lfvIBA
# Ph.D.
# High SchooVOther
# people involved in continuous process improvement
Direct
Indirect
Fraction of time the workforce is idle
Expressed as a percentage
Average weekly overtime hrs for packaging employees
Aver_Ie nwnber of weekly ovenmx hours worked by producllon employees only
Average hours of training I Total work hours (packaging employees)
FDA stipulated training
On the job training
Off the job training
Other training
Total # of people involved in packaging QC and QA
Machines:
Plant value at time of construction or purchase
% yrly operating budget u&...d for equipment enhancements
Average age of packaging equipment
Cost of capital assumed in making investments in equipment _
Performance of packaaioa::
Cost/Productivity
Total cost of final packages
Total cost of final packages includes direct materials, direct labor, & overhead.
Production overhead cost
Maintenance expenses
Maintenance eXFenses defined as total expenses in repairs and improvements for
production buildings and equipment.
Total value of average packaging work-in-process
Tina mcludea all marenaJ 1D p:oceas and excludes raw malcnal lDventcry or fuushed gocxls mvenoory
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Total value of average packaging inventories held
Include .U fuusbed goods and mtennedJate goods ready filr slupmenl 10 Internal or external cu!lomers
What do you perceive as bein~ your inventory holding cost? _
Express~ as a percent. cost of capital
Quality
Lots manufactured right first time / Total lots manufactured
Loti nghl finl tlme are lor. nOC reJecled. rete:ned. rellupccred or reprocessed
ProdUCI reprocessed before lolal process complcnon IS counted nol manufactured nghl lsI hme
Add1Uonal testmg rcquued WI IS outside of nonnal praCtlce IS cowned not manufactured nght lsI hme
Lor. held pcnchng funber le.bog or approval are counted II:! nOC rmnufactured ngill lSI tllDe
Percentage of initiated lots that are:
Rejected by packaging (waste)
Repr()f~essed by packaging
Rejected by cy::JQA
Retested by ~/QA
# of 483 citations by FDA related to packaging
Major
Minor
Time/Flexibility/Service
Number of new packagings introduced into packaging
Average capacity utilization of facility
Annual operating hours
Annual hrs reqdjor preventative maintenance & turnovers
Annual hrs the equipment is idle
Degree of computer automation
On a scale of (1) to (5) rate the degree of automation for the site with (1) being mostly
manual and (5) being mostly automated (elM) .
New product ramp-up time
If a new product was mtroduced. how long (m weeks) was It before the fmt two CODSel.utlve batches
were mmufactured nghl the first tune
Number of significant process-plant modifications
Significant defined as requiring revalidation, FDA approval, or factory shutdown
in excess of 1 production week. Exc1udes product turnover.
Trigger for process-plant modification:
External (FDA, EPA, Customer, etc.)
Internal (ideas submitted, continuous improvement, QC, etc.)
Actual prodn. / Aggregate forecast requirements
Actual prC'dn of active in~-edient (Kgs) at year end (external or internal customers)
Forecast are the initial production requirements at the beginning of production year (Kgs)
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Safety!Morale:
# suggestions submitted by packaging employees
Any work place or proceu re laced luggesbons
# suggestions made by packaging maintenance employees
Any work place or proceu related suggestion
Include aalmcd and hourly employees. but exclude management and adnuruslrabon
# of suggestions submitted by packaging QC/QA personnel
Any work place or procesa related suggestlorl.
Total number of ideas submitted that were implemented
Total # of safety related incidents n'lated to pack~gi!lg
Lost workday cases per 100 packaging employees
Total number of 1011 workdays 1 [nwnber of employees 1100]
Packaging employee job absence rate
Number of worker-days lost through lIbecoce 1 Total number of worker days
Packaging employee turnover
Number of separations I Avcmge number employees 00 payroll
Turnover figures cover all pennanent separabons. whether voluntary or mvoluntary
Tins docs r.ol mclude employees placed on temporary layoff or retirements
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OUTBOUND LOGISTICS:
Outbound logistics involves activities that associated with collecting, storing and physically distributing the
product such as finished goods warehousing, material handling, delivery vehicle operation, order
processing, and scheduling.
MEASURE:
Inputs into outbound IOKistics process:
People
Number of people involved in outbound logistics
Direct
Indirect
Experience of people involved in outbound logistics
Years of service.
1990 1991 1992 1993
Education of people
Breakdown by degree: #B.S.
#M.S./MBA
# Ph.D.
# High SchoolJOther
Materials
Cost of materials sold
Methods
Number of customers
Average length of contracts
Dollars spent of customer service training
Time to switch customers (in weeks)
Machines
Use of Infonnation Technology (Scale of 1 to 5)
1 indicates Manual, 2 a frrst generation MRP system, 5 indicates
electronic data interchange with customer.
Performance of outbound logistics process:
Cost/Productivity:
Average finished goods inventory level
Mcuwed m producbon weeks
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Quality:
Total complaints / Number of units
Total complaints include "customer" and FDA complaints.
"Customerll includes any user (internal or external) of finished or intermediate goods
Units measured as 1 Kilo for Bulk Chern. 1()() tablets for tablets and one container for all other
If a customer complaint is made against an entire 10 Kilo delivery, this counts as 10 complaints
Time/FlexibilityIService:
Average QC release time turnaround for fmished goods
Measured in hours, from the time goods are completed to the time QC
officially releases goods for shipment or sale
Average length of QC hold on finished goods
The average time (in days) finished goods are held in storage by QC
because of potential abnormalities
Average actual fmished goods test time
Average actual test run-time, measured in hours.
Number of due dates missed / Total number of deliveries
Deliveries are to the "customer" (i.e.. pharmaceutical manufacturer. next chemical plant, stock,
or marketing) This includea internal or external customers. Partial shipments are considered
missed due dates. Re negotiated shipping dates are considered missed due date.
Lead time between delivery and order placement (in weeks)
Average time the fmished good sits in inventory (in weeks)
Total Floor Space dedicated to inbound logistics (sq. ft)
Average distance traveled by finished goods (ft)
Safety/Morale:
# of safety related incident in outbound logistics
#of safety related lost work days in outbound logistics
# suggestions made by employees in outbound logistics
Any work place or prooesa related suggesbons
-------~--------------------------~--------------~---------~~~~----------~------
# of ideas submitted that were implemented
From qucitiODS II I and '2 above
Employee job absence rate in outbound logistics
Number of worker-days lost through absence I Total number of worker days
Employee turnover in outbound logistics
Nu.mbrer of IqhlratJODl I Avemgc number employees 00 payroll
Turnover figures cover all permanent tepatabous. whether voluntary or mvo!untary
Ths doca not lIKlude employees placed on temporary layoff or retlremc:I&ts
--------------~--------~-~----------~----~-----~------------~-~-----------------
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Total number of employees
Total employees 15 total plmll populatIon
Total Plant size
Annual plant revenues
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